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ABSTRACT

Griffin M. Wright, Ph.D.,University of South Alabama, May 2022. STAT3
DYSREGULATION OF XRCC1 RESULTS IN ALTERED BASE EXCISION REPAIR.
Chair of Committee: Michele Schuler, Ph.D.
Base Excision Repair (BER) is a critical DNA repair pathway, repairing base
damage, the spontaneous decay of bases, abasic sites, and single-strand DNA breaks.
BER requires the sequential action of multiple proteins, including poly(ADP ribose)
polymerase 1 (PARP1), X-ray cross complementing group 1 (XRCC1), and DNA
polymerase beta (POL 𝛽). Expression changes and polymorphisms in BER proteins alter
the response of cancer cells to multiple DNA damaging chemotherapeutics, with
overexpression of XRCC1 increasing chemoresistance in gastric, gallbladder, and ovarian
cancer. However, the transcriptional regulation of XRCC1 remains largely understudied.
Here, we identify the signal transducer and activator of transcription 3 (STAT3) as a
novel regulator of XRCC1 in TNBC cell line models, the osteosarcoma cell line U2OS,
and the human embryonic kidney cell line HEK293T. Glucose, epidermal growth factor
(EGF) and interleukin 6 (IL-6) are all known to activate STAT3 and promote
transcription We have found that this constitutive activation results in persistent
occupancy of STAT3 at the XRCC1 promoter in TNBC cell lines, inducing
overexpression of XRCC1 protein. However, the non-tumorigenic HEK293T cell line
and osteosarcoma U2OS cell line do not have constitutively activated STAT3 but
demonstrate an inducible response to the activation of STAT3 from exogenous stimuli.
Using acute exposures to EGF, IL-6, and glucose, we observed increased
activated STAT3 and subsequent increases in XRCC1 expression in HEK293T and

xvi

U2OS cells. Critically, the increased XRCC1 expression induced by high glucose
exposure resulted in increased DNA repair, measured through alkaline comet assay, and
increased survival following methyl methanesulfonate (MMS) challenge in both
HEK293T and U2OS cells. Furthermore, continued exposure to elevated glucose
concentrations resulted in persistent STAT3 occupancy at the XRCC1 promoter and
elevated XRCC1 expression in both HEK293T and U2OS cells, similar to what is seen in
constitutively active TNBC cell lines. Low glucose adaption reversed these effects by
reducing STAT3 activation and occupancy at the XRCC1 promoter in the HEK293T
U2OS cells. However, low glucose adaptation in the MDA-MB-231, which have
constitutively active STAT3, only slightly reduced STAT3 activation. Upstream
regulators of STAT3 revealed a correlation between IL-6R𝛼 expression and the
inducibility of STAT3 activation and subsequent XRCC1 expression. High EGFR
expression and low IL-6R𝛼 expression resulted in minimal inducibility of MDA-231. In
addition to these findings, we also identified POLB as a target for STAT3 regulation and
mapped the STAT3 binding site within the POLB promoter.
These results demonstrate that activation of STAT3 regulates XRCC1 expression
and altered BER functions across various cell line models. More importantly, it links
constitutive activation of STAT3 with dysregulation of XRCC1 and BER in TNBC cells
and undercovers a critical mechanism by which XRCC1 can become dysregulated in
cancer and promote chemoresistance.

xvii

CHAPTER I: BACKGROUND

Base Excision Repair
It is estimated that each cell is subjected to 70,000 DNA damaging events daily,
75% of which are single-strand breaks 1.

Figure 1.1. Base Excision Repair Pathway. Schematic representation of the BER
pathway including multiple key enzymes PARP1, XRCC1, POL𝛽, and LIG3𝛼. This
Figure was generated using Biorender.com with citation provided in Appendix B.

1

If DNA damage persists within the genome, mutations can arise and drive transformation.
Thus, DNA repair is critical in maintaining genomic stability 1,2. Base excision repair
(BER) is responsible for repairing DNA base lesions, the spontaneous decay of DNA
bases, and single-strand breaks resulting from the endogenous and exogenous insults the
cell faces 2-4. In particular, BER is essential in repairing mutagenic DNA base
modifications resulting from oxidation and alkylation of DNA bases, both of which can
lead to non-Watson Crick base pairing and subsequent mutations 5. The BER pathway is
initiated by a DNA glycosylase, which recognizes and removes damaged DNA bases.
DNA glycosylases belong to two families, mono-functional and bi-functional DNA
glycosylase (Figure 1.1, Appendix B) 6. Both mono-functional and bi-functional DNA
glycosylases contain glycosylase activity, the ability to cleave glycosidic bonds; however,
bi-functional glycosylases also have Apurinic/Aprimidine (AP) lyase activity catalyzing
the cleavage of phosphodiester bonds 2,6. Following base removal by a mono-functional
glycosylase, an AP endonuclease (APE1) is needed to form the single-strand DNA breaks
2,3.

Single strand DNA breaks formed during the BER process are then recognized and

bound by Poly(ADP Ribose) polymerase 1 (PARP1) 2,3,7. Following binding to the DNA
single-strand break, PARP1 undergoes an auto-modification by ADP-ribose, resulting in
the formation of Poly ADP Ribose (PAR) chains 7,8. PAR chains are responsible for
recruitment of BER factors, including X-ray cross complementing protein 1 (XRCC1)
7,9,10.

The BRCTa domain of XRCC1 interacts with PARylated PARP1 bound to a single-

strand break and serves as a scaffold protein responsible for the binding and facilitation
of multiple BER factors, including DNA polymerase Beta (POL 𝛽) through the Nterminal domain and DNA Ligase III Alpha (LIGIIIα) through the C-terminal BRCT
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domain 9. POL 𝛽 removes the 5’-deoxyribose phosphate group following the action of
APE1 2,3,9,11. In addition, POL 𝛽 serves as the primary gap-filling polymerase during the
BER process 11. LIGIIIα finalizes the repair process by catalyzing the formation of a
phosphodiester bond between the inserted DNA nucleotide and the adjacent DNA
nucleotide 2,3.
Transcriptional Regulation of XRCC1
Although XRCC1 plays a critical role in maintaining genomic stability, little is
known regarding its transcriptional regulation (Figure 1.2, Appendix A) 1,12. Two
transcription factors have been identified in the regulation of XRCC1, Sp1 and E2
transcription factor 1 (E2F1) 13,14. Basal transcription of XRCC1 occurs through the
binding of Sp1 to a GC rich target sequence upstream of the transcription start site 13.
However, following persistent DNA damage, activation of the DNA damage sensor,
ataxia telangiectasia mutated (ATM), results in the phosphorylation and degradation of
Sp1, resulting in reduced XRCC1 expression promoting apoptosis 13. The cell cycle
regulator E2F1 serves as a transcription factor with a consensus binding sequence
upstream of the Sp1 site 14. E2F1 regulation of XRCC1 is responsible for inducing a
robust repair response following DNA damage induced by MMS 14. Outside of E2F1 and
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Sp1, no other transcription factors sites within the XRCC1 promoter have been
extensively studied.

Figure 1.2. Transcriptional Regulation of XRCC1: Two Transcription Factors
have been identified in the regulation of XRCC1; Sp1 serves as the basal
transcription factor and is negatively regulated through an ATM dependent
phosphorylation, E2F1 is responsible for producing a robust increase in XRCC1
following MMS-induced DNA damage. This figure was adapted from
“Transcriptional dysregulation of base excision repair proteins in breast cancer”
published in DNA Repair with the journal’s permission provided in Appendix A.

Transcriptional Regulation of POLB
Transcriptional regulation of POLB has been more extensively studied, with six
transcription factors regulating POLB expression (Figure 1.3, Appendix A) 12. Like
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XRCC1, Sp1 is responsible for driving the basal expression of POLB by increasing the
rate of RNA polymerase promoter closed complex formation 15.

Figure 1.3. Transcriptional Regulation of POLB: Like XRCC1, Sp1 serves as a
basal transcription factor of polymerase beta. Multiple cell line specific regulatory
mechanisms have been identified including TEIF regulation in HeLa cells and NFkB regulation in EBV B-cells. PKA activation following alkylating DNA damage
induces CREB-1 phosphorylation and subsequent regulation of POLB. An ATF-1
site has been proposed but not validated. This figure was adapted from
“Transcriptional dysregulation of base excision repair proteins in breast cancer”
published in DNA Repair with the journal’s permission provided in Appendix A.

An activating transcription factor 1 (ATF-1) site has been proposed but not
validated 16. Increased expression of POLB following alkylating DNA damage has been
reported through cAMP-dependent protein kinase A (PKA) phosphorylation of cAMP
responsive element binding protein 1 (CREB-1), increasing the binding of the
transcription factor to the POLB promoter 17,18. POLB regulation in specific cell lines has
also been reported, including Telomerase transcriptional element-interacting factor
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(TEIF) regulation of POLB in HeLa cells as well as regulation of POLB through the
Epstein Barr virus-associated activation of Nuclear Factor Kappa-light-chain-enhancer of
activated B cells (NF-kB) by associated viral protein latent membrane protein 1 (LMP1)
19,20.

Transcriptional Regulation of PARP1
PARP1 has multiple roles outside of its DNA repair duties, including modulation
of transcription either as a transcription factor or by regulating the activity of other
transcription factors through post-translation modification, including Yin-yang 1 (YY-1),
Activating protein 2 (AP-2) and STAT3 21-24. Like POLB, transcriptional regulation of
PARP1 has been more widely studied with five identified transcription factors (Figure
1.4, Appendix A) 12. Sp1 binds a GC rich region within the PARP1 promoter and
regulates the basal transcription of PARP1 12,23. However, in rats, the regulation by Sp1 is
inhibited by the binding of nuclear factor 1 (NF1) to the GC rich Sp1 binding site,
blocking the binding of Sp1 to the PARP1 promoter 25. Additionally, PARP1 regulates its
own expression through the PARylation of Sp1, reducing the DNA binding ability of Sp1
to its target sequence in the PARP1 promoter 23. YY-1 has been shown to regulate the
transcription of PARP1 through a putative binding site within the PARP1 promoter 22.
However, this regulation is altered during DNA damage through YY-1 mediated
increases in enzymatic activity of PARP1, but during severe stress, YY-1 is PARlyated
reducing the binding activity of YY-1, subsequently reducing PARP1 transcription 22.
AP-2 also has a putative binding site within the PARP1 promoter. A dual regulatory role
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has been proposed for AP-2 in which AP-2 is activated by PARP1 and inactivated by
PARylation 21.

Figure 1.4. Poly(ADP Ribose) Polymerase 1 Transcriptional Regulation: Sp1 and
Sp3 have been shown to drive the basal transcription of PARP1. A cell specific
mechanism has been proposed in Ewing’s Sarcoma through the action of ETS.
YY-1 drives PARP1 expression but is also regulated itself by PARP1 following
DNA damage. A dual regulatory mechanism has been proposed but not verified
for AP-2 and NFI has been shown to bind the Sp1 site within the PARP1 promoter
blocking the action of Sp1. This figure was adapted from “Transcriptional
dysregulation of base excision repair proteins in breast cancer” published in DNA
Repair with the journal’s permission provided in Appendix A.

Base Excision Repair and Cancer
The BER pathway plays a major role in maintaining genomic stability;
thus, single nucleotide polymorphisms (SNPs) in BER proteins and alterations in BER
protein expression occur in multiple cancers 5. SNPs have been observed in various BER
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proteins, including XRCC1 and POL 𝛽. The XRCC1 variant Arg399Gln is associated
with increased risk of prostate cancer and postmenopausal breast cancer 26,27. Mutations
in POL 𝛽 have been observed in 30% of human tumors. These mutations are not found in
the germline but have functional phenotypes associated with reduced polymerase or lyase
activity 5. SNPs in APE1 and other DNA glycosylases have also been identified in many
cancers 5. Beyond mutations, alterations in BER protein expression are also found in
numerous cancers 4,5,28,29. Elevated XRCC1 expression occurs in gastric, ovarian,
gallbladder, and breast cancers 4,30-32. Upregulation of XRCC1 alters cisplatin response in
gastric and ovarian cancer, while low expression increases sensitivity to PARP inhibitors
in breast cancer 30-34. Increased POL 𝛽 expression occurs in breast, colon, and prostate
cancer tissue samples 35.
Our lab has identified dysregulation of BER proteins in Triple Negative Breast
Cancer (TNBC) cells lines 4. TNBC accounts for 15-20% of breast cancer cases and is the
deadliest of breast cancer subtypes with high metastasis and recurrence rates 4,36-38.
TNBC is characterized by the lack of estrogen receptor (ER) and progesterone receptor
(PR) expression as well as no human epidermal growth factor receptor 2 (HER2)
amplification 4,36-38. Breast cancer treatment was revolutionized with the discovery of
hormone and targeted therapeutics such as monoclonal antibodies 39. However, due to the
receptor status, TNBC is unresponsive to molecularly targeted therapies such as
tamoxifen and trastuzumab, which have become mainstay treatment options for hormone
receptor-positive breast cancers and HER2 amplifying breast cancers, respectively 36,39,40.
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The lack of these targets results in a primary systemic treatment course for TNBC
consisting of chemotherapeutics used in both the neoadjuvant and adjuvant setting.
Dysregulation of BER in breast cancer requires further investigation due to the
critical role that estrogen metabolism plays in the promotion as well as maintenance of
breast cancer 41,42. Outside of its role in driving breast cancer cell proliferation, estrogen
also presents a problem in maintaining genomic stability 43. During estrogen metabolism,
reactive oxygen species (ROS) and depurinating adducts are generated 41. ROS interacts
with DNA bases, resulting in oxidized DNA bases, most commonly guanine due to its
low redox potential, resulting in DNA mutation through non-Watson Crick base pairing
promoting transversion guanine to thymine mutations 44. BER repairs oxidative DNA
damage by recognizing and removing the damaged base with specific DNA glycosylases
6,44.

Metabolism of estrogen also results in the formation of depurinating estrogen-DNA

adducts, ultimately resulting in the formation of abasic sites on DNA. APE1 then
recognizes abasic sites, promoting the formation SSBs, which are then repaired by the
overlapping BER and single-strand break repair pathways 2,3.
Our lab has identified dysregulation of BER proteins including XRCC1, POL 𝛽,
and PARP1 in TNBC cell lines, the most aggressive form of breast cancer 4.
Additionally, dysregulation of these BER factors resulted in a varied response to MMS
and other DNA damaging agents 4,37.

Signal Transducer and Activator of Transcription 3 (STAT3)
The signal transducer and activator of transcription (STAT) family is a sevenmember group of transcription factors: STAT1, STAT2, STAT3, STAT4, STAT5a,
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STAT5b, and STAT6. STAT1 is associated with increased tumor suppression signaling,
including interleukin 12 (IL-12) and interferon gamma (IFN𝛾); thus, increased STAT1
activation in multiple cancer is associated with better clinical outcomes 45,46. Like
STAT1, STAT2 plays a tumor-suppressive role. This has been illustrated by increased
tumor formation in STAT2-deficient mice 46,47. STAT3 is the only STAT family
transcription factor whose deletion is embryonically lethal 46. STAT3 is highly associated
with cancer growth, immune evasion, metastasis, and cancer development. It is widely
regarded as an oncogene with aberrant activation of STAT3 occurring in 70% of human
cancers, including breast cancer 46. High STAT3 activation is associated with poor
clinical outcomes 46. Although its role in cancer is not widely studied, increased
expression of STAT4 is a positive prognostic factor in breast, ovarian, and gastric cancer
46.

STAT5 consists of two proteins that share 94% homology, STAT5a and STAT5b.

STAT5 has been described to have both tumor-suppressing and tumor-promoting roles.
STAT5 serves as a poor prognostic marker in prostate cancer and is associated with
migration and invasion 46. However, in breast cancer, STAT5a and STAT5b have a
tumor-suppressive role, and high expression serves as a positive prognostic marker 46.
Increased STAT6 expression is associated with poor clinical outcomes through its role in
metastasis in breast, prostate, and gastric caners 46.
STAT3 signaling serves as a critical mediator of normal mammary development,
in particular the process of involution, the process by which mammary glands undergo
massive cell death and remodeling returing to the pre-preganant state 48. STAT3 has been
widely described as a cancer-promoting oncogene by regulating target genes associated
with multiple cancer-associated processes, including anti-apoptosis, proliferation,
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angiogenesis, and metastasis. These target genes include c-MYC, BCL-2, Cyclin D1,
Vimentin, VEGF-A, IL-6, and survivin, which are detailed further in 49.

Figure 1.5. Canonical STAT3 Signaling STAT3 is activated by multiple cytokines, growth
factors, and inflammatory associated signaling pathways. Canonically STAT3 is activated
through the binding IL-6 to the IL-6R resulting in the activation and phosphorylation of JAK
and STAT3. Additionally, STAT3 is activated through the binding of EGF to EGFR resulting
in STAT3 phosphorylation. Following phosphorylation, STAT3 dimerizes and shuttles into
the nucleus, binding the consensus sequences within its target genes. This Figure was
generated using Biorender.com with citation provided in Appendix B.
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Constitutive activation of STAT3 through sustained phosphorylation of the Y705 residue
has been documented in numerous cancer types, including breast cancer 45,50.
Canonical signaling of STAT3 involves the binding of cytokines and growth factors,
including IL-6 and epidermal growth factor (EGF) to their respective receptors (Figure
1.5, Appendix B) 50-53. Following ligand binding, receptor-associated Janus kinases
(JAKs) are activated and undergo transphosphorylation of the cytoplasmic tail of the
receptor 51. Tyrosine phosphorylation serves as a docking site for unphosphorylated
STAT3 51. STAT3 is then phosphorylated at Y705 and subsequently homodimerizes. 51.
Homodimerized STAT3 then undergoes nuclear translocation where it can bind target
sequences on genes through the action of the DNA binding domain 51,53.
STAT3 is constitutively activated in 40% of breast cancer cases 50-53. Among the
breast cancer subtypes or subclasses with constitutively activated STAT3 is TNBC.
TNBC most commonly gains constitutive activation of STAT3 through sustained
autocrine and paracrine signaling of IL-6 50. STAT3 phosphorylation is tightly regulated
through a series of negative regulators, including suppressors of cytokine signaling
(SOCS), protein inhibitor of activated STAT (PIAS), and various phosphatases 50,54.
During constitutive activation of STAT3, a breakdown in these negative regulators
occurs, allowing for sustained signaling promoting STAT3 signaling 50,54.
The following work aimed to investigate transcriptional dysregulation of BER
proteins XRCC1, POL 𝛽, and PARP1 in TNBC and determine whether the mechanism of
transcription regulation translated to other tissues. I hypothesize that STAT3 regulates
BER proteins XRCC1, POL 𝛽, and PARP1 promoting the dysregulation of BER. The
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constitutive activation and transcriptional activities of STAT3 made it a unique potential
regulator for BER factors in TNBC and likely other cancers.
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CHAPTER II: STAT3 SERVES AS A NOVEL TRANSCRIPTIONAL
REGULATOR OF XRCC1

Introduction
There are significant gaps in our understanding of the transcriptional regulation of
multiple BER proteins, XRCC1, POL 𝛽, and PARP1. As noted, two transcription factors
have been identified to regulate XRCC1 expression- Sp1, the basal regulator of XRCC1,
and E2F1, the cell cycle-associated transcription factor 13,14. XRCC1 serves as a critical
scaffold protein in the BER pathway coordinating and facilitating other BER factors,
including POL 𝛽 and DNA LIGIII𝛼. Outside of BER, XRCC1 has also been implicated
in other DNA repair pathways, including nucleotide excision repair and alternative nonhomologous end joining 55-58. XRCC1 is ubiquitously expressed in most tissues, and
knockout of XRCC1 is embryonically lethal in mice 59-61. Overexpression of the BER
protein XRCC1 has been observed in breast cancers, including TNBC.
Breast cancer is the second most diagnosed cancer in women in the United States,
accounting for 42,000 new cancer cases in 2017. Triple Negative Breast Cancer (TNBC)
accounts for 15-20% of breast cancer cases and is the deadliest of breast cancer subtypes
with high metastasis and recurrence rates 4,36-38. TNBC is characterized by the lack of
estrogen receptor (ER) and progesterone receptor (PR) expression as well as no human
epidermal growth factor receptor 2 (HER2) amplification 4,36-38. Targeted therapeutics for
hormone receptors and related enzymes have revolutionized breast cancer treatment 39.
However, the receptor status of TNBC makes it unresponsive to molecularly-targeted
therapies such as tamoxifen and trastuzumab, which have become mainstay treatment

14

options for hormone receptor-positive breast cancers and HER2 amplified breast cancers,
respectively 36,39,40. For TNBC, the primary treatment course consists of neo-adjuvant
DNA damaging chemotherapeutics following surgical resection and radiation. The
Cancer Genome Atlas (TCGA) expression portal UALCAN shows a significant increase
in XRCC1 transcripts per million in TNBC samples compared to normal breast samples
62.

Overexpression of XRCC1 has been shown to increase resistance to the first-line

chemotherapeutics, including cisplatin 30-33,63. Conversely, low XRCC1 expression
increases the efficacy of PARP inhibitors 33,34. As a result, a greater understanding of the
transcriptional regulation of XRCC1 would provide a biomarker or a therapeutic target to
increase cancer cell killing. However, our knowledge about transcription factors driving
this overexpression is currently lacking.
STAT3, an oncogene, is a transcription factor that regulates a host of cancerrelated genes, including those involved in inflammation 49. STAT3 is constitutively
activated in a host of cancers, including TNBC. In TNBC, autocrine and paracrine
production of IL-6 results in sustained activation of STAT3 50. This is further exacerbated
due to the critical role STAT3 as in the regulation of the IL-6 gene, meaning STAT3
activation results in a positive feedback loop further increasing STAT3 activation 49,50,64.
Additionally, autonomous production of IL-6 occurs in TNBC tumor cells 50,64. Here, we
identify STAT3 as a novel regulator of XRCC1 in TNBC, providing a potential
mechanism driving resistance to DNA damaging chemotherapeutics. The results
presented here were adapted from “Activated STAT3 Is a Novel Regulator of the XRCC1
Promoter and Selectively Increases XRCC1 Protein Levels in Triple Negative Breast
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Cancer” published in International Journal of Molecular Sciences with the journal’s
permission provided in Appendix A 65.

Material and Methods
Chemicals
Alantolactone was acquired from Selleckchem (Selleckchem #S8318) and
resuspended in anhydrous DMSO to a concentration of 15mM. Carboplatin was acquired
from Sigma (Sigma #C2538) and resuspended in molecular grade water. A solution of
Doxorubicin in DMSO was obtained from Selleckchem (Selleckchem #S1208).
Cell Culture
MDA-MB-231(MDA-231), MDA-MB-468 (MDA-468), and HEK293T were
purchased from the American Type Culture Collection (ATCC HTB-26, HTB-132, and
CRL-3216, respectively; Manassas, VA, USA) within the last 24 months and passaged <
15 times for all experiments. Cells were tested biweekly during experiments for
mycoplasma contamination using the Lonza MycoAlert® (Lonza #LT07-318). MDA-231
and MDA-468 cells were grown in DMEM High Glucose + GlutaMAX™ (Life
Technologies, Carlsbad, CA, USA, #10566016) and supplemented with 1% sodium
pyruvate (Life Technologies, #11360070) and 10% FBS (Premium Select, R&D systems,
Minneapolis, MN, USA). HEK293T cells were grown in DMEM High Glucose + LGlutamine (HyClone, Logan, UT, USA, # SH30022.01) and supplemented with 1%
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sodium pyruvate (Life Technologies #11360070) and 10% FBS. Cells were maintained in
a humidified 37 °C incubator with 5% carbon dioxide.
Promoter Luciferase Reporter Assay
Transcriptional activity at the XRCC1 promoter was measured using a dual
promoter-luciferase assay similar to those previously reported 14,65. The pGL3 plasmid
containing the full-length XRCC1 promoter from Chen et al. was provided by Dr. Charles
Lopez (Oregon Health Sciences University, Portland, OR, USA). XRCC1 promoter
fragments XRCC1, ∆766, ∆612, ∆310, and ∆35 were cloned using XRCC1 promoterspecific primers from genomic DNA harvested from MDA-231 cells. Promoter PCR
fragments were digested with Nhel Anza™ (Thermo Fisher Scientific, Waltham, MA,
USA, #IVGN0066) and NcoI Anza™ (Thermo Fisher Scientific#IVGN0026) and then
ligated into a pGL3 plasmid backbone with Anza™ T4 DNA Ligase (Thermo Fisher
Scientific #IVGN2104). The final plasmid constructs with the correct promoter fragment
insertion were confirmed by Sanger sequencing by Eurofins. MDA-231 cells were
transfected with 0.4 µg of plasmid DNA and 0.1 µg of pRSV β galactosidase plasmid
DNA using Jetprime (Polyplus transfection, New York, NY, USA, #114−15, 1:6).
HEK293T cells were transfected with 0.4 µg of plasmid DNA and 0.1 µg of pRSV β
galactosidase plasmid DNA (Promega, Madison, WI, USA) using Jetprime transfection
reagent (1:2). pGL3 was used as a negative control to ensure the assay worked correctly.
Using the β-Galactosidase Enzyme Assay System with Reporter Lysis Buffer (Promega
#E2000) and the Luciferase Assay System (Promega #E1500), transfected cells were
lysed 24 h after transfection, and luminescence and absorbance were collected using an
Infinite® M1000 PRO, TECAN (Mannedorf, Switzerland). Luminescence values were
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normalized to the respective β-galactosidase absorbance to control for transfection
efficiency. The assay was performed in parallel plates in technical triplicate over three
biological replicates. Results represent the average of the three biological replicates ±
standard error of the mean (SEM).
In Silico Transcription Factor Search
Potential transcription factor targets for the XRCC1 promoter were identified
using multiple in silico softwares. First, an Encode database search was performed to
identify transcription factors binding the promoters of interest. CiiiDER
(www.ciiider.org) was used to identify potential transcription factor binding sites. IgV
browser was used to further identify potential transcription factor binding sites.
Transcription Factor Binding Plate
Potential transcription factors binding the XRCC1 promoter were identified using
the transcription factor binding array (Signosis Santa Clara, CA, USA #FA-1001-NE).
Following the manufacturers’ instructions, nuclear extracts were isolated from MDA231, and the binding of transcription factors was tested using the XRCC1 full length
and XRCC1 ∆35 PCR products described in the promoter-luciferase sections. The
promoter binding ELISA was performed with two biological replicates, using Sp1 as a
positive binding control.
Chromatin Immunoprecipitation
MDA-231, MDA-468, and HEK293T cells were grown to confluency in a 150
mm dish. The cells were crosslinked by adding 1% formaldehyde in DMEM with gentle
rocking at room temperature (RT ~23 °C) for 8–10 min. Then, 0.1 M glycine was added
for 5 min at RT to quench the formaldehyde. The cells were washed with cold 1×
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phosphate-buffered saline (PBS) and subsequently lysed with 1 mL of farnham lysis
buffer (5 mM HEPES pH 8.0, 85 mM KCl. 0.5% NP-40) for 20 min on ice, then pelleted
by centrifugation at 2000 rpm and resuspended in RIPA buffer (50mM Tris-HCl pH 8,
150mM NaCl, 1% sodium deoxycholate, 1mM EDTA, 0.1% SDS, 1% Triton X-100) for
20 min. Isolated chromatin was then sonicated on ice at an amplitude of 12 on a Misonix
S-4000 with 15 s on/50 s off for a total process time of 2.5 min for MDA-231 and MDA468 and amplitude of 10 on a Misonix S-4000 with 15 s on/50 s off for a total process
time of 3.5 min for HEK293T. Chromatin was incubated overnight at 4 °C on a rotator
using an anti-STAT3 antibody diluted to manufacture’s recommendations for chromatin
immunoprecipitation (Cell Signaling Technology, Danvers, MA, USA #9131S), an antiSp1 antibody (Abcam Cambridge, MA, USA #ab13370) diluted 1:100 as a positive
control, a mouse IgG isotype control (Cell Signaling Technology #5415S) and with
Protein A/G magnetic beads (Thermo Fisher Scientific #88802). Magnetic beads were
washed with cold LiCl wash buffer (100 mM Tris-HCl, 500 mM LiCl, 1% NP-40, 1%
Triton X-100) and TE Buffer (10mM Tris-HCl pH 7.5, 0.1mM EDTA). Proteinase K
(VWR Life Science Radnor, PA, USA # E195-5ML) was then added with ChIP Elution
Buffer (1% SDS, 0.1 M NaHCO3) and incubated at 65 °C 950 rpm for 2 h. Proteinase K
was then inactivated at 90 °C for 10 min. DNA was purified using a PureLink PCR
Purification Kit (Life Technologies #K310002 kit). An IgV browser was used to design
primers examining the occupancy across the XRCC1 promoter.
Western Blotting
Briefly, the cells were grown in 150 mm dishes and cultured to 70–80%
confluence. Cells were rinsed with PBS, scraped, stored overnight at −80 °C, then lysed.
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Protein content was quantified using a Bradford assay. Then, 20 µg of lysate was
separated on 7.5% or 4–15% SDS Page gel (Bio-Rad #s, 4561025 and 4561084) and
transferred to a nitrocellulose membrane. Membranes were blocked in 5% non-fat dry
milk in Tris-buffered saline (VWR #J640-4L) containing 0.1% Tween20 (Thermo Fisher
Scientific #BP337, TBS-T) and raised against the following primary antibodies: XRCC1
(1:1000 #MS434P1) from Fisher Scientific (Pittsburgh, PA, USA); STAT3 (1:1000,
#9139) and pSTAT3 Y705 (1:500, #9131) from Cell Signaling Technology, Inc.; and αtubulin (1:5000, #T9026) from Millipore Sigma (St. Louis, MO, USA). The blots were
incubated with either of the horseradish peroxidase (HRP)-labeled secondary antibodies:
goat anti-rabbit-HRP or goat anti-mouse-HRP (#7074P2 and #7076S respectively) from
Cell Signaling Technology, Inc. HRP antibody target proteins were detected by
incubating with WesternBright Sirius (Advansta San Jose, CA, USA #K-12043-D20). All
immunoblotting was conducted with three biological replicates. Where indicated, protein
quantification was conducted with Image Lab Software (Bio-Rad, Hercules, CA, USA).
Band intensity was normalized to loading controls and averaged over the three biological
replicates with SEM presented.
Gene Expression and qPCR
Relative gene expression was performed through mRNA isolation from MDA231, MDA-468, and HEK293T cell lines using Invitrogen Cell to Ct kit (Life
Technologies #4399002). Following the manufacturers’ recommendations, the cells were
plated in a 96-well plate, and the untreated cells were grown to 75% confluency. For
transfection, 0.1 μg of plasmid DNA was added with Fugene 6 transfection reagent in a
1:6 ratio (plasmid DNA to Fugene). Cells were then allowed 48h to recover before being
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lysed for mRNA isolation using an Invitrogen Cell to Ct kit (Life Technologies
#4399002). The cells were then lysed, and RT-PCR was performed to produce cDNA
using the reagents from the kit. After cDNA synthesis, qPCR was performed using
TaqMan Gene expression primers XRCC1 (Hs00959834_m1 FAM), STAT3
(Hs00374280_m1 FAM), and Actin (Hs01060665_g1 VIC) and the TaqMan master mix
provided with the kit (Applied Biosystems Foster City, CA, USA #4369016). The assay
was performed in technical triplicate over three biological replicates. Results represent
the average of the three biological replicates ± standard error of the mean (SEM).
Modulation of STAT3
Plasmid constructs for stable depletion of human STAT3 mRNA, pSIH-puroSTAT3 shRNA (referred two as shRNA #1), and its control were gifts from Frank
Sinicrope (Addgene plasmid #26596 and #26597; Watertown, MA, USA). An additional
shRNA construct specific for STAT3 (shRNA Clone ID:NM_003150.3-458s21c1
referred to as shRNA #2 hereafter) and the pLKO.1 control were purchased from SigmaAldrich (St. Louis, MO, USA). Both shRNA constructs and their controls were used to
validate the STAT3 binding site and expression changes. MDA-231 cells were plated at
200,000 cells/well in a 6-well culture plate. After 48 h, cells were transfected with 5 μg
plasmid DNA (shRNA# 1 or 2 or appropriate vector control) and FuGene 6 (Promega) at
a 1:6 ratio (DNA to FuGene). Cells were allowed to recover for 48h following
transfection. STAT3 was overexpressed using a pcDNA3.1+ STAT3 ORF clone from
Genscript (Piscataway, NJ, USA) with a C-terminal Flag-tag. MDA-231 cells were plated
at 200,000 cells/well in a 6-well culture plate, and HEK293T were plated in 10 cm plates
at 500,000 cells/plate. After 48 h, MDA-231 cells were transfected with 5 μg of plasmid
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DNA (STAT3-FLAG and proper vector control) and Fugene 6 (Promega) in a 1:6 ratio
(DNA to Fugene). HEK239T cells were transfected with 10 μg of plasmid DNA
(STAT3-FLAG and proper vector control) and Jetprime transfection agent at a 1:2 ratio
(DNA to Jetprime). 48 h post-transfection, cells were rinsed with 1X PBS, plates were
scraped, and the pelleted cells were stored overnight at −80 °C. Immunoblot was then
performed as described below.
Cytokine and Growth Factor Exposure
Cytokine exposure was performed using recombinant Human IL-6 protein (R&D
Systems, Minneapolis, MN, USA, #206-IL-010/CF). IL-6 was aliquoted in PBS at 100
µg/mL concentration and stored at −80 °C for no longer than three months before use, as
recommended by the manufacturers. Aliquoted IL-6 and EGF were added to the cell
culture medium to a final concentration of 50ng/mL and 30ng/mL, respectively. MDA231 and HEK293T cells were plated in 15 mm dishes and cultured to 70–80%
confluency. Cells were then exposed to IL-6 at a final concentration of 50ng/mL for 30
min, 1 and 4 h, and EGF at a final concentration of 30ng/mL for 1, 4, and 24 h. Cells
rinsed with 1X PBS plates were scraped, and pelleted cells were stored overnight at −80
°C. Immunoblot was performed as described above.
XRCC1-RFP Cloning
Stable transfection of XRCC1-RFP overexpressing clones was accomplished
using Fugene 6 transfection agent as described above. Briefly, cells were plated in a 6
well dish allowing 24 h to adhere. Cells were then transfected with XRCC1-RFP vectors,
allowing 48 h to recover. Following recovery, puromycin selection medium was then
added to cells. Following selection, cells were transferred to a 96-well culture dish at a

22

density of 1 cell-per-well and maintained in puromycin selection medium. Single-cell
colonies were then expanded and frozen in liquid nitrogen. XRCC1-RFP transfection into
MDA-231 clones was confirmed using immunoblot.
Growth Inhibition Assay
Cell counts were aquired for XRCC1-RFP using cell counting and STAT3-FLAG using
Cell-titer Glo® (Promega #G7570). For growth inhibition using cell counting, cells were
plated at a density of 2X104 (MDA-231) in 12 well-dishes and allowed 48 h to adhere.
Stably transfected MDA-231 XRCC1-RFP and parental MDA-231 cells were then treated
with 5,10, 20, and 40 𝜇M carboplatin and 10,25,50, 75, and 100nM doxorubicin. Cells
were allowed to recover for 5 days before being trypsinized and resuspend in 1mL of
PBS. Resuspended cells were counted using BioRad TC10 Automated Cell Counter. Cell
counts were performed in triplicate normalized to control wells for a total of three
biological replicates. Values were plotted as mean ± standard error of mean (SEM). Cell
Titer Glo was performed per the manufacture’s instruction. Briefly, cells were plated
(2X103) in a 96 well cell culture dishes, allowing 24 h to adhere. Cells were then
transiently transfected as described above with STAT3-FLAG expression vectors.
50ng/mL IL-6 was predosed 30 min prior to challenge with carboplatin followed by
continuous 50ng/mL IL-6 dosing in MDA-231. Cells were then dosed with 0, 50, 100,
250, 500, and 1000𝜇M carboplatin. Luminescence was then collected using an
Infinite® M1000 PRO, TECAN (Mannedorf, Switzerland).
Statistical Analysis
Assays were performed as three biological replications. One-way ANOVA and
means were compared with Dunnett’s post hoc analysis. Comparison groups are indicated
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in graphs. All means are reported ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001,
**** p < 0.0001.

Results
A novel regulatory site exists in the XRCC1 promoter
A promoter-luciferase assay was performed first to assess the potential for a novel
regulator of XRCC1. PCR fragments from sequential segments of the XRCC1 promoter
were cloned and inserted into a pGL3 plasmid. Luminescence collected from MDA-231
and HEK293T revealed a potential novel regulatory site not associated with either
previously identified transcription factor, E2F1 and Sp1 (Figure 2.1). These findings
showed sustained luminescence through the -310 site, differing from those previously
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reported in the SAOS2 osteosarcoma cell line 14. With these findings, we next wanted to
investigate the potential for a novel transcription factor binding the XRCC1 promoter.

Figure 2.1. Reporter assay indicates a novel regulatory region in XRCC1. A) XRCC1
promoter fragments with known transcription factor sites inserted into the pGL3
luciferase reporter. B) Reporter plasmids were transfected into MDA-231 and
luminescence read after 24 h. C) Reporter plasmids were transfected into HEK293T and
luminescence read after 24 h ****p<0.0001. This figure was adapted from “Activated
STAT3 is a Novel Regulator of the XRCC1 Promoter and Selectively Increases XRCC1
Protein Levels in Triple Negative Breast Cancer” published in IJMS with the journal’s
permission provided in Appendix A.

25

The XRCC1 promoter contains a STAT3 binding site
Using a transcription factor binding ELISA, potential transcription factor
candidates were identified.

Figure 2.2. Promoter Binding ELISA Identifies STAT3. A) Full Length (FL) and
∆35 luminescence in specific transcription factor coated wells; STAT3, Sp1, CBF,
NF1, HNF4, and a Negative control.

Binding to the XRCC1 full length promoter (FL) occurred in several transcription
factors, including Sp1 (positive control), CBF, NF1, HNF4, and STAT3 (Figure 2.2).
To further explore the potential transcription factors acquired from the ELISA, in silico
searches were performed using IgV Browser and CiiiDER. IgV browser uses publicly
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available ChIP seq data from the Encode database to show potential DNA binders and
histone modification to the genome at genes of interest. CiiiDER is a predictive tool to
identify transcription factor binding sites within a DNA region of interest. IgV browser
searches revealed a potential STAT3 binding site within the XRCC1 promoter
corresponding to the region identified from the promoter-luciferase assay. This potential
STAT3 binding site was further affirmed through the input of the XRCC1 promoter into
the CiiiDER program.
Now armed with a potential transcription factor and a region of interest, we
sought to confirm the binding site within the XRCC1 promoter. Using ChIP, the binding
of STAT3 to the XRCC1 promoter was mapped in the MDA-231 (Figure 2.3). A
significant enrichment above the IgG control was seen at a region corresponding to the
sequence identified by the promoter-luciferase assay and in silico searches. The highest
enrichment occurred at a 96 base pair region -452 to -358 (2.426 ± 0.11), downstream of
the E2F1 binding site but upstream of the Sp1 binding. Sp1 was used as a positive
control, and a non-binding region in the genome was selected as a negative control to
ensure the experiment was performed with high fidelity. MDA-468 also showed a
significant enrichment at the same 96 base pair region (1.826 ± 0.066). The binding of
STAT3 to the XRCC1 promoter was attenuated following shRNA-mediated knockdown
of STAT3 in MDA-231 (0.868 ± 0.11) compared to the respective vector control (1.67 ±
0.14). Analysis of the 96 base pair region revealed a potential consensus binding
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sequence for STAT3. Together these data show that STAT3 binds to the XRCC1
promoter. We next wanted to explore the role that STAT3 has in regulating XRCC1.

Figure 2.3. The XRCC1 promoter contains a STAT3 binding site. A) The CiiDER
identified STAT3 binding sequence within the XRCC1 promoter (red font). B)
CHiP analysis of XRCC1 promoter in MDA-231 cells show a significant
enrichment of STAT3 between -452 and -358. C) Knockdown of STAT3 with
shRNA #1 eliminates the STAT3 binding within the -452 to -358 fragment. D)
STAT3 binding also occurs within the -452 to -358 fragment of the XRCC1
promoter in MDA-468 cells. **p< 0.01, ****p<0.0001. This figure was adapted
from “Activated STAT3 is a Novel Regulator of the XRCC1 Promoter and
Selectively Increases XRCC1 Protein Levels in Triple Negative Breast Cancer”
published in IJMS with the journal’s permission provided in Appendix A.

Modulation of STAT3 results in attenuated XRCC1 expression
To test the role that STAT3 plays in the regulation of XRCC1, we first performed an
shRNA-mediated knockdown of STAT3 using two different shRNA constructs to control
for potential off-target effects.
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Figure 2.4. shRNA knockdown of STAT3 reduces the expression of XRCC1 in
MDA-231 cells. A) Representative immunoblots of phospho-STAT3 (Y705),
STAT3 and XRCC1 protein expression following shRNA mediated knockdown of
STAT3. α-tubulin is used as a loading control. B) Quantification of protein
expression changes in XRCC1 resulting from shRNA-mediated knockdown of
STAT3. C) Quantification of XRCC1 mRNA expression following shRNAmediated knockdown of STAT3. *p< 0.05, **p< 0.01, ***p<0.001, ****p<0.0001.
This figure was adapted from “Activated STAT3 is a Novel Regulator of the
XRCC1 Promoter and Selectively Increases XRCC1 Protein Levels in Triple
Negative Breast Cancer” published in IJMS with the journal’s permission provided
in Appendix A.
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Figure 2.5. shRNA knockdown of STAT3 reduces the expression of XRCC1 in
MDA-468 cells. A) Representative immunoblots of phospho-STAT3 (Y705),
STAT3 and XRCC1 protein expression following shRNA mediated knockdown of
STAT3. α-tubulin is used as a loading control. B) Quantification of protein
expression changes in XRCC1 resulting from shRNA-mediated knockdown of
STAT3. C) Quantification of XRCC1 mRNA expression following shRNAmediated knockdown of STAT3. *p< 0.05, **p< 0.01, ***p<0.001, ****p<0.0001
* . This figure was adapted from “Activated STAT3 is a Novel Regulator of the
XRCC1 Promoter and Selectively Increases XRCC1 Protein Levels in Triple
Negative Breast Cancer” published in IJMS with the journal’s permission provided
in Appendix A.

Knockdowns were performed in the MDA-231 and MDA-468. 48 h following shRNA
knockdown of STAT3 gene expression analysis and immunoblots were performed to see
changes in XRCC1 gene and protein expression, respectively. STAT3 attenuation by
shRNA resulted in a significant reduction of XRCC1 gene expression in MDA-231 (sh#1
0.506 ± 0.089 and sh #2 0.693 ± 0.015) (Figure 2.4) and in MDA-468 (sh#1 0.626 ±
0.11 and sh #2 0.554 ± 0.10) (Figure 2.5), indicating a decrease of XRCC1 associated
mRNA. Knockdown of STAT3 resulted in a significant reduction of pSTAT3, the active
STAT3 species, total STAT3, and XRCC1 protein expression in MDA-231 (sh#1 0.435
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± 0.019 and sh #2 0.313 ± 0.063) and MDA-468 (sh#1 0.511 ± 0.066 and sh #2 0.445 ±
0.079). These data indicate a potential role for STAT3 in the regulation of XRCC1.
Pharmacological inhibition of STAT3 attenuates XRCC1 expression
Pharmacological inhibition of STAT3 was used to confirm the role that STAT3 plays in
the regulation of XRCC1. The STAT3 inhibitor alantolactone was used at a 15 𝜇M for 4
and 24 h, which resulted in a significant reduction of pSTAT3. Attenuation of active
STAT3 resulted in a significant reduction of XRCC1 gene expression and protein
expression at 4 h (0.675 ± 0.038 and 0.649 ± 0.051) (Figure 2.6). Inhibition of active
STAT3 in MDA-468 with 15 𝜇M for 4 h also resulted in a significant reduction of
XRCC1 gene and protein expression (0.758 ± 0.20 and 0.760 ± 0.026).
STAT3 ectopic expression and exogenous exposures stimulate XRCC1 expression
Knowing that attenuation of STAT3 through shRNA-mediated knockdown and
pharmacological inhibition resulted in an attenuation of XRCC1 expression, we next set
out to see if stimulation of STAT3 increased XRCC1 expression. STAT3 expression was
increased in MDA-231 cells through the transfection of a STAT3-FLAG ectopic
expression vector. Following transfection, STAT3 and active STAT3 were significantly
increased, resulting in a significant increase in XRCC1 protein expression (2.07 ± 0.19)
(Figure 2.7). STAT3-FLAG transfection also resulted in a significant increase in XRCC1
gene expression compared to the vector control (3.52 ± 0.086). Next, we wanted to test if
increased STAT3 activation resulted in increased XRCC1 protein and gene expression.
We exposed MDA-231 cells to IL-6 and EGF, both of which are known to stimulate
STAT3 activation. Following exposure to IL-6 (50 ng/mL) for 30 min, 1 and 4 h, a nonsignificant increase in XRCC1 protein occurred at all time points, but a significant
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increase in XRCC1 gene expression occurred at all three time points (1.81 ± 0.25, 1.68 ±
0.14, and 1.66 ± 0.14 30 min, 1, and 4 h, respectively) (Figure 2.8).

Figure 2.6. Chemical inhibition of the phosphorylation of STAT3 at Y705 by
alantolactone decreases the expression of XRCC1 in MDA-231 and MDA-468 cells. A)
Representative immunoblots of phospho-STAT3 (Y705), STAT3 and XRCC1 protein
expression after 4 h exposure to 15 µM alantolactone in MDA-231 cells. α-tubulin is
used as a loading control. B) Quantification of protein expression changes in XRCC1
resulting from 4 h alantolactone exposure in MDA-231 cells. C) Quantification of
XRCC1 mRNA expression following 4 h alantolactone exposure in MDA-231 cells. C)
Representative immunoblots of phospho-STAT3 (Y705), STAT3 and XRCC1 protein
expression after 4 h exposure to 15 µM alantolactone in MDA-468 cells. B)
Quantification of protein expression changes in XRCC1 resulting from 4 h alantolactone
exposure in MDA-468 cells. C) Quantification of XRCC1 mRNA expression following 4
h alantolactone exposure in MDA-468 cells. **p< 0.01, ***p<0.001, ****p<0.0001.
This figure was adapted from “Activated STAT3 is a Novel Regulator of the XRCC1
Promoter and Selectively Increases XRCC1 Protein Levels in Triple Negative Breast
Cancer” published in IJMS with the journal’s permission provided in Appendix A.
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MDA-231 were exposed to EGF (30 ng/mL) for 1, 4, and 24 h. Subsequent
protein expression revealed an increase in STAT3 activation and an increase active

Figure 2.7. Ectopic overexpression of STAT3 increases the expression of XRCC1 in
MDA-231 cells. A) Representative immunoblot of phospho-STAT3 (Y705), STAT3
and XRCC1 protein expression following ectopic expression of STAT3-FLAG. αtubulin is used as a loading control. B) Quantification of protein expression changes in
XRCC1 resulting from ectopic expression of STAT3-FLAG. C) Quantification of
XRCC1 mRNA expression following ectopic expression of STAT3-FLAG. **p< 0.01,
****p<0.0001. This figure was adapted from “Activated STAT3 is a Novel Regulator
of the XRCC1 Promoter and Selectively Increases XRCC1 Protein Levels in Triple
Negative Breast Cancer” published in IJMS with the journal’s permission provided in
Appendix A.
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STAT3 expression at 24 h post-EGF exposure, resulting in a significant increase in
XRCC1 expression (1.73 ± 0.061) (Figure 2.9).

Figure 2.8. IL-6 increases phospho-STAT3 and increases the expression of XRCC1 in
MDA-231. A) Representative immunoblot of phospho-STAT3 (Y705), STAT3 and
XRCC1 protein expression after 1 and 4 h exposure to 50 ng/mL IL-6. α-tubulin is
used as a loading control. B) Quantification of protein expression changes in XRCC1
resulting from 50 ng/mL IL-6 exposure. C) Quantification of XRCC1 mRNA
expression following 50 ng/mL IL-6 exposure. *p< 0.05. This figure was adapted from
“Activated STAT3 is a Novel Regulator of the XRCC1 Promoter and Selectively
Increases XRCC1 Protein Levels in Triple Negative Breast Cancer” published in IJMS
with the journal’s permission provided in Appendix A.

This also translated to a non-significant increase in XRCC1 gene expression at all
three time points. Taken together, these data indicate STAT3 regulates XRCC1
expression in TNBC cell lines.
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Figure 2.9. EGF increases phospho-STAT3 and increases the expression of XRCC1 in
MDA-231. A) Representative immunoblot of phospho-EGFR(Y1068), EGFR, phosphoSTAT3 (Y705), STAT3 and XRCC1 protein expression after 1, 4, and 24 h exposure to
30 ng/mL EGF. α-tubulin is used as a loading control. B) Quantification of protein
expression changes in XRCC1 resulting from 30 ng/mL EGF. C) Quantification of
XRCC1 mRNA expression following 30 ng/mL EGF. **p< 0.01. This figure was
adapted from “Activated STAT3 is a Novel Regulator of the XRCC1 Promoter and
Selectively Increases XRCC1 Protein Levels in Triple Negative Breast Cancer”
published in IJMS with the journal’s permission provided in Appendix A.

STAT3 occupancy of the XRCC1 promoter occurs only following STAT3 activation
Because TNBC has constitutively active STAT3, we next wanted to see if the
STAT3 regulation of XRCC1 occurred in a TNBC specific mechanism. HEK293T has a
lower expression of STAT3 and pSTAT3 and a lower STAT3 occupancy of the XRCC1
promoter (1.49 ± 0.28) compared to TNBC cell lines MDA-231 (2.43 ± 0.19) and MDA468 (1.82 ± 0.073) (Figure 2.10). To test if the STAT3 regulatory mechanism of XRCC1
in the HEK293T was inducible, we wanted to stimulate STAT3 activation and STAT3
expression using the STAT3-FLAG ectopic expression vector in the HEK293T. We
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found that the STAT3 occupancy of the XRCC1 promoter significantly increased to the
level seen in the TNBC cell lines MDA-231 (2.43 ± 0.19) and MDA-468 (1.82 ± 0.073)
only following ectopic expression of STAT3 in HEK293T (3.93 ± 1.00) (Figure 2.11).

Figure 2.10. STAT3 occupancy of the XRCC1 promoter across cell lines. ChIP analysis
of the XRCC1 promoter (-452 to -358) in MDA-231, MDA-468, and HEK293T,
normalized to the respective IgG controls *p<0.05, **p< 0.01, ***p<0.001,
****p<0.0001. This figure was adapted from “Activated STAT3 is a Novel Regulator
of the XRCC1 Promoter and Selectively Increases XRCC1 Protein Levels in Triple
Negative Breast Cancer” published in IJMS with the journal’s permission provided in
Appendix A.

However, this ectopic expression of STAT3 did not significantly increase the
protein expression of XRCC1 in the HEK293T (1.03 ± 0.035).
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STAT3 regulation of XRCC1 requires stimulation in the HEK293T

Figure 2.11. Ectopic overexpression of STAT3 increases the STAT3 occupancy within
the XRCC1 promoter. A) CHiP analysis of STAT3 binding to the -452 to -358 XRCC1
promoter fragment. *p< 0.05. B) Representative immunoblots of phospho-STAT3
(Y705), STAT3 and XRCC1 protein expression following ectopic expression of
STAT3-FLAG. α-tubulin is used as a loading control *p<0.05. This figure was adapted
from “Activated STAT3 is a Novel Regulator of the XRCC1 Promoter and Selectively
Increases XRCC1 Protein Levels in Triple Negative Breast Cancer” published in IJMS
with the journal’s permission provided in Appendix A.

To further probe the regulatory mechanism occurring in the HEK293T, we next
stimulated the cell line using the inflammatory cytokine IL-6. IL-6 stimulates the
phosphorylation of STAT3 at the Y705 residue, resulting in homodimerization,
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subsequent nuclear translocation, and binding of STAT3 homodimers to target sequences
on genes as introduced in Figure 1.5 53,54.

Figure 2.12. IL-6 increases phospho-STAT3, increases the occupancy of STAT3 at
the XRCC1 promoter, and increases the expression of XRCC1 in HEK293T. A)
Representative immunoblot of phospho-STAT3 (Y705), STAT3 and XRCC1
protein expression after 1 and 4 h exposure to 50 ng/mL IL-6. α-tubulin is used as a
loading control. B) CHiP analysis shows IL-6 increases the STAT3 occupancy on
the XRCC1 promoter. C) Quantification of protein expression changes in XRCC1
resulting from 50 ng/mL IL-6. D) Quantification of XRCC1 mRNA expression
following 50 ng/mL IL-6. *p<0.05, **p< 0.01, ***p<0.001. This figure was
adapted from “Activated STAT3 is a Novel Regulator of the XRCC1 Promoter and
Selectively Increases XRCC1 Protein Levels in Triple Negative Breast Cancer”
published in IJMS with the journal’s permission provided in Appendix A.
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HEK293T were dosed with IL-6 (50ng/mL) for 30 min, 1, and 4 h
immunoblotting revealed an increase of pSTAT3 and XRCC1 with a significant peak of
XRCC1 protein occurring at 4 h (mean ± SEM) and a significant increase in XRCC1
gene expression at all three time points (1.51 ± 0.13, 1.57 ± 0.13, and 1.82 ± 0.15,
respectively) (Figure 2.12). Because the largest increase in XRCC1 gene and protein
expression occurred at 4 h, HEK293T were exposed to IL-6 (50ng/mL) for 4 h to test for
changes in occupancy of the XRCC1 promoter. ChIP revealed a significant increase in the
STAT3 occupancy of the XRCC1 promoter (2.20 ± 0.32) to a level comparable to that
seen in the MDA-231 (2.43 ± 0.19). These data suggest that the constitutive activation of
STAT3 occurring through IL-6 autocrine and paracrine signaling in the TNBC cell lines
promotes dysregulation of XRCC1.
Overexpression of XRCC1 increases resistance to carboplatin and doxorubicin
Due to the widely reported role of XRCC1 expression on the modulation of
chemotherapeutic response, we next wanted to test if increased XRCC1 expression
independent of STAT3 could alter carboplatin and doxorubicin response. Using the
ectopic expression vector for XRCC1, XRCC1-RFP, we found a significant increase in
XRCC1 independent of STAT3. Stably transfected XRCC1-RFP MDA-231 cells were
isolated and subjected to increasing concentrations of carboplatin. Two MDA-231
XRCC1-RFP clones, XRCC1-RFP clone 2 and XRCC1-RFP clone 7, showed increased
resistance to carboplatin as indicated by increased IC 50 values compared to in MDA-231
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parental cells (Figure 2.13). Increased resistance was also seen for doxorubicin for
XRCC1-RFP clone 2 compared to MDA-231 parental cells (Figure 2.14).
Alteration in response to carboplatin following STAT3 modulation

Figure 2.13. Increased expression of XRCC1 results in increased carboplatin
resistance independent of STAT3. MDA-231 XRCC1-RFP clones (Clone 2 and Clone
7) were generated and exposed to carboplatin; values are percentage of cell survival
compared to untreated controls.

Having found increased resistance to carboplatin with XRCC1 overexpression
independent of STAT3, we wanted to test if increased STAT3 and STAT3 activation also
resulted in increased resistance to carboplatin. Using the STAT3 ectopic expression
vector STAT3-FLAG, STAT3 was overexpressed in MDA-231 cells through the
transient transfection. A slight increase in resistance, an increase in IC50, to carboplatin,
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was seen for STAT3-FLAG transfected cell lines compared to vector controls (Figure
2.15). To test if increased STAT3 activation resulted in increased resistance to
carboplatin, MDA-231 cells were pretreated with 50ng/mL of IL-6 for 30 min then
continuously dosed with IL-6 and carboplatin. IL-6 treatment resulted in a slight increase
in the IC50 following carboplatin treatment compared to parental MDA-231.

Figure 2.14. Increased expression of XRCC1 results in increased doxorubicin
resistance independent of STAT3. MDA-231 XRCC1-RFP clone were generated and
exposed to doxorubicin; values are percentage of cells compared to unexposed
controls.
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Figure 2.15. Increased STAT3 expression and activation increases
resistance to carboplatin in MDA-231. A) STAT3-FLAG transiently
transfected MDA-231 (48 h) were exposed to increasing concentrations
of carboplatin. B) MDA-231 cells were pre-treated with 50ng/mL of IL-6
for 30 min, then co-exposed to carboplatin and IL-6.
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Discussion
Dysregulation of DNA repair proteins is a hallmark of cancer. Changes in the
expression of DNA repair proteins can increase susceptibility to DNA damaging
therapies or increase chemoresistance 4,37. While various factors can regulate gene
expression, transcription factors play a critical role in basal transcription and response to
stress and stimuli. Despite BER's crucial role in addressing exogenous and endogenous
threats, our knowledge of the transcription factors that regulate BER factors is lacking
12,17

. Surprisingly, only two transcription factors, E2F1 and Sp1, have been identified in

the transcriptional regulation of XRCC1 13,14.
This study has identified a novel regulator of XRCC1, STAT3, which selectively
upregulates XRCC1 in TNBC. Previously, we showed that XRCC1 gene and protein
expression alterations occur across a panel of TNBC cell lines 4. Here, we determined
that STAT3 binds within the XRCC1 promoter in MDA-231, MDA-468, and HEK293T
cells (Figures 2.3, 2.10, and 2.11). Yet, the site only has significant occupancy when
STAT3 is activated. Constitutive activation of STAT3 occurs in the TNBC cells and is
reflected by increased occupancy at the binding site (Figure 2.3). However, pSTAT3 is
low in the HEK293T cells, and occupancy at the STAT3 binding site in the XRCC1
promoter is similarly low (Figure 2.10). This conditional regulation may explain why the
promoter assay shows stable output between -612 and -310, despite the STAT3 site being
deleted in the -310 construct (Figure 2.1).
shRNA-mediated knockdown of STAT3 significantly reduced both the gene and protein
expression of XRCC1 (Figure 2.4). Importantly, it also reduced the occupancy at the
STAT3 binding site within the XRCC1 promoter in MDA-231 cells (Figure 2.3). We
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further confirmed the dependence on activated, phosphorylated STAT3 (Y705) by
chemical inhibition with alantolactone. Alantolactone targets the SH2 domain of STAT3
and prevents phosphorylation at Y705 66. In the presence of 15 μM alantolactone, we
again showed a significant reduction in both gene and protein expression of XRCC1
(Figure 2.6).
Given that TNBC cell lines showed higher levels of pSTAT3, we examined
physiologically relevant stimuli that could lead to activated STAT3 and increased
XRCC1 expression. Several reports have demonstrated that inflammatory signaling
through IL-6R promotes constitutive activation in TNBC 67-69. These signaling events are
proposed to play a role in breast cancer development and progression through aberrant
signaling 68. Using IL-6, we demonstrated that STAT3 is activated in HEK293T and
MDA-231 and subsequently increases the gene and protein expression of XRCC1
(Figures 2.8). More importantly, we showed that IL-6 increased the occupancy of STAT3
at the STAT3 binding site within the HEK293T XRCC1 promoter, which showed low
occupancy under normal growth conditions (Figure 2.12).
These data provide evidence that STAT3 is a conditional regulator of XRCC1 in
response to stress and inflammatory signals. Under normal physiological conditions,
activation of STAT3 is tightly controlled by several intrinsic inhibitors, including protein
tyrosine phosphatases, the suppressors of cytokine signaling, and the protein inhibitor of
activated STAT 51. These regulatory mechanisms allow STAT3 to exert its physiological
functions and limit the aberrant signaling seen in cancer. The low level of STAT3 and
pSTAT3 in the HEK293T cells confirmed the tightly checked role of STAT3 in these
non-tumorigenic cells and demonstrated that STAT3 does not drive XRCC1 expression in
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this cell line. Interestingly, the ectopic overexpression of STAT3 increased the levels of
pSTAT3 and the occupancy of STAT3 at the XRCC1 promoter in HEK293T but did not
increase the expression of XRCC1 (Figure 2.11). However, after stimulation with IL-6,
we see a dramatic increase in the presence of activated pSTAT3 and increased XRCC1
protein and gene expression (Figure 2.12). Therefore, the expression and activation of
STAT3 alone is not enough to stimulate the transcription of XRCC1 in this nontumorigenic cell line.
Transformation involves numerous cellular and genomic changes that reduce
inhibition on growth and proliferation signals. These changes also reduce apoptotic
signaling and cell cycle control mechanisms as well as alter DNA damage response. As a
result, we the see overexpression of STAT3 being sufficient to drive XRCC1 expression
in the MDA-231 cells (Figure 2.7). Stimulation by exogenous exposures IL-6 and EGF
also resulted in increased XRCC1 expression (Figure 2.8 and 2.9). These results are
consistent with two recent studies which examined the role STAT3 plays in regulating
growth and invasion in TNBC cell lines 70,71. Both studies used ChIP-seq to examine the
transcriptional regulation of genes by STAT3. While their focus was on proliferation,
migration, and invasion genes, examination of the ChIP-seq results (GSE85579 and
GSE152203) at the XRCC1 promoter showed STAT3 binding sites within the MDA-MB231, MDA-MB-468, and HCC70 cells 70,71. These ChIP-seq results in basal-like TNBC
cell lines support our findings of higher expression and activation of STAT3, resulting in
increased XRCC1 expression 4,70,71. Further validation of pSTAT3 dependence of these
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sites is needed to better understand the impact of conditional regulation of XRCC1 by
pSTAT3 in TNBC.
The more blunted response in HEK293T cells and reports of under-expression of
XRCC1 in hormone-positive breast cancers suggest that activated STAT3 regulation of
XRCC1 may be highly tissue-specific and dependent on exogenous signals like IL-6 or
EGF 34. Tissue specificity is supported by the finding that stimulation by IL-6 is more
robust than the ectopic expression alone (~ 3-fold vs. 2-fold) in HEK293T. The
difference in expression from IL-6 vs. ectopic STAT3 may be related to the
downregulation of inhibiting factors, such as SOCS3, or could reflect the additional
changes in redox balance and reactive species induced by IL-6 68,72-74. Additional studies
are needed to differentiate these contributors in the STAT3-related transcriptional control
of XRCC1, though, in all likelihood, these mechanisms are probably interrelated.
In TNBC, IL-6 plays a critical role in breast cancer growth and maintenance
64,68,74.

TNBC tumor cells can autonomously produce IL-6, resulting in the constitutive

activation of STAT3 64,74. Activated STAT3 acts as a transcription factor controlling the
expression of genes involved in regulating cell proliferation, anti-apoptosis, migration,
invasion, angiogenesis, chemoresistance, immune escape, and autophagy 75. Here, for the
first time, we have linked STAT3 activation by cytokines and stress factors to regulating
a DNA repair protein, XRCC1. In our previous work with TNBC cell lines, we noted
over-expression of XRCC1 in pre-clinical TNBC cell lines, which contrasted with
previous reports in hormone-positive breast cancers noting a deficiency in XRCC1
expression 4,33,34,37. In examining the effects of XRCC1 over-expression, we noted
resistance to the alkylating agent MMS in highly over-expressed XRCC1 cell lines. Other
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reports have associated the up-regulation of XRCC1 with increased risk of breast cancer,
poor survival across low and high-risk breast cancer subtypes, increased tumor
aggressiveness, and resistance to cisplatin, PARP inhibitors, and ionizing radiation
28,34,61,76.

However, the mechanism driving the overexpression of XRCC1 in TNBC and

other cell lines has not been identified. Here, we show that XRCC1 overexpression,
independent of STAT3, increases carboplatin and doxorubicin resistance. Likewise,
increasing STAT3 expression and STAT3 activation through STAT3 ectopic expression
and IL-6 exposure resulted in increased resistance to carboplatin. These data indicate a
role for STAT3 regulation of XRCC1 expression in the development of chemoresistance
in TNBC.
We reversed MMS resistance through shRNA-mediated knockdown of XRCC1
expression 4. Additionally, the under-expression of XRCC1, seen in some hormonepositive breast cancers, is correlated with increased sensitivity to chemotherapeutics,
including ionizing radiation, cisplatin, and PARP inhibitors 28,33,34,77. Together, these
results suggest that attenuation of XRCC1 expression influences breast cancer etiology
and response to therapy. While we have identified pSTAT3 as a novel regulator of
XRCC1 in TNBC, it is also likely that activated STAT3 regulates XRCC1 under stress
and growth conditions in non-tumorigenic cells. However, it is not until pSTAT3 levels
become dysregulated that sustained increases in XRCC1 expression and subsequent
changes in BER and SSBR would be observed, contributing to chemoresistance and
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tumor aggressiveness. The constitutive activation of STAT3 in TNBC allowed this
regulation to be identified more readily.
This work illuminates the complex regulatory mechanisms for BER proteins like
XRCC1. Dysregulation of DNA repair proteins is a hallmark of cancer, yet basal and
stress-induced regulatory mechanisms for these proteins are poorly delineated 12,17. Here,
we have identified a stress-specific regulatory mechanism for increasing protein levels of
XRCC1, which becomes dysregulated in TNBC, and potentially other cancers.
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CHAPTER III: HIGH GLUCOSE INDUCES XRCC1 EXPRESSION RESULTING
IN INCREASED DNA REPAIR FOLLOWING DAMAGE

Introduction
Changes in the balance of DNA repair proteins contribute to cancer initiation,
progression, and treatment. Somatic and germline mutations, altered epigenetic
regulation, and overexpression of DNA repair proteins are observed in various cancers,
but the underlying mechanisms are just beginning to be unraveled. While dysfunction of
DNA repair proteins through their loss or mutations has garnered significant research
focus, factors driving the overexpression of DNA repair proteins and improving DNA
repair capacity in cancer cells are not well understood.
We have identified dysregulation of DNA repair proteins in TNBC cells that alter
the DNA repair capacity of these cells 4,37. We also recently linked overexpression of
XRCC1, BER protein, to the transcriptional activities of STAT3 65. BER is essential to
repairing the myriad of DNA base lesions accumulated from endogenous and exogenous
exposures daily. XRCC1 has no enzymatic function but serves as a scaffold protein
facilitating the actions of other DNA repair proteins 2,9. Although it lacks enzymatic
activity, XRCC1 plays a critical role in efficient BER repair, and deletion of XRCC1 is
embryonically lethal. In addition to its role in BER, XRCC1 has been shown to function
in multiple other DNA repair pathways, including nucleotide excision repair (NER),
through its interaction with DNA ligase III𝛼 and double-strand break repair through its
interactions with PARP1 in alternative non-homologous end-joining 55,58. XRCC1 is
dysregulated in multiple cancers beyond breast cancer 4. XRCC1 overexpression has been
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shown to increase resistance to DNA damaging chemotherapeutics in gastric and ovarian
cancers, while low XRCC1 is correlated with hypersensitivity to DNA damaging agents
30-32,34,78,79.

However, little is known about the transcriptional regulation of XRCC1 and

the exposures that drive dysregulation 13,14.
Since the discovery of the Warburg effect over a century ago, the role of glucose
in cancer formation and progression has seen increased attention. Chronic inflammation
and hyperglycemia result in increased prevalence and mortality associated with many
cancers, including breast and colorectal 80-83. Normal circulating blood fasting glucose
concentrations range from 3.9 mmol/L to 5.6 mmol/L, and acute hyperglycemia is
defined by a circulating glucose concentration of 6.1 mmol/L to 11.0 mmol/L 84.
Inflammation and hyperglycemia also induce oxidative stress and DNA damage that are
significant factors contributing to disease development and progression 85,86. While there
has been considerable focus on changes in antioxidant systems and regulatory responses
driven by nuclear-erythoid 2-related factor 2 (NRF2) and NFκB, several studies have
noted DNA damage and repair changes 85.
Hyperglycemia causes DNA lesions and strand breaks and alters the DNA
damage response in renal and prostate cancers 87,88. Notably, a reduction in the expression
of DNA repair proteins involved in nucleotide excision repair, homologous
recombination, and mismatch repair were observed 87-89. Chemo- and radiation resistance
was also noted in normal renal epithelial cells and renal cell carcinoma after high glucose
exposure and is attributed to altered DNA damage response and reduced repair, though
DNA repair protein expression changes were not examined 87. Alterations in XRCC1
gene and protein expression were reported following glucose concentration changes in
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breast cancer cell lines and hepatocytes, suggesting differences in the response between
tissue and cell types 79,90.
Our previous work demonstrated that STAT3 was a novel regulator of XRCC1 in
TNBC cell lines, which have constitutive activation of STAT3 50,65. STAT3
transcriptional activities are induced by phosphorylation at tyrosine 705 (Y705), leading
to dimerization and translocation into the nucleus 91. STAT3 activation following high
glucose exposure has been documented in numerous cell lines 92,93. We also found that
STAT3 serves as an inducible regulator of XRCC1 in the non-tumorigenic human
embryonic kidney cell lines HEK293T 65. However, no links between increased glucose
concentrations, activation of STAT3, and increased XRCC1 and DNA repair have been
made.
This study identified high glucose concentrations as a driver of XRCC1
expression through increased STAT3 activation. We show increased STAT3 activation
across cell line models following acute high glucose exposure, resulting in increased
resistance to DNA damaging agents. Continuous exposure to high glucose concentrations
promoted sustained STAT3 activation and XRCC1 expression, demonstrating that
dysregulation of XRCC1 and DNA repair is achieved through STAT3 activation across
different cell types.

Materials and Methods
Chemicals
Methyl Methanesulfonate (MMS) was acquired from Sigma Aldrich (Sigma
#129925) and diluted in media to the desired concentrations. Alantolactone was acquired
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from Selleckchem (Selleckchem #S8318) and resuspended in anhydrous DMSO to a
concentration of 15mM.
Cell Culture
HEK293T, U2OS, and MDA-MB-231 were purchased from the American Type
Culture Collection (ATCC CRL-3216, HTB-26, and HTB-96, respectively) within the
last 24 months and passaged < 10 times for all experiments (passage numbers from 6-15).
Biweekly test mycoplasma contamination was performed using the Lonza MycoAlert
(Lonza #LT07-318). HEK293T cells were grown in DMEM High Glucose + LGlutamine (Hyclone #SH30022.01) supplemented with 1% sodium pyruvate and 10%
Fetal Bovine Serum (FBS). U2OS cells were grown in RPMI 1640 with L-glutamine
(Corning 10-040-CV) supplemented with 10% FBS. MDA-231 cells were grown in
DMEM High Glucose + Glutamax (Life Technologies, #10566016) supplemented with
1% sodium pyruvate and 10% FBS.
Low glucose adapted HEK293T and MDA-231 were grown in DMEM low
glucose, pyruvate (Thermo Fisher Scientific #11885084) supplemented with L-glutamine,
1% sodium pyruvate, and 10% FBS. Low glucose adapted U2OS were grown in RPMI
1640 with L-glutamine without Glucose (Life Technologies #11879020) supplemented
with 5mM glucose (D-(+)-Glucose Solution Sigma #G8644) and 10% FBS.
Immunoblot
Immunoblot was performed as previously described. Briefly, cells were grown in
150mm dishes and grown to 80% confluency. 1XPBS was used to rinse cells before cells
were scraped and pelleted at 1000rpm and stored overnight at -80℃. Pellets were then
lysed, and a Bradford assay quantified protein content before 20𝜇g of lysate was
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separated on 4-15% SDS Page gel (Bio-Rad #4561084) and transferred to nitrocellulose
membrane (Bio-Rad #1704156EDU). Nitrocellulose membranes were blocked for 1 h at
RT in 5% non-fat dry milk in Tris-buffered saline (VWR #J640-4L) containing 0.1%
Tween20 (Thermo Fisher Scientific #BP337, TBS-T). Primary antibodies were incubated
overnight: XRCC1 (1:1000 #MS434P1, Fisher Scientific), pSTAT3 Y705 (1:500 Cell
Signaling Technology, #9131), STAT3 (1:1000 Cell Signaling Technology, #9139),
pEGFR (1:500 Cell Signaling Technology, #3777) EGFR (1:1000 Cell Signaling
Technology #4267), IL-6R𝛼 (1:1000 Cell Signaling Technology #39837). Blots were
incubated with the proper horseradish peroxidase (HRP)-labeled secondary antibodies
(goat anti-rabbit-HRP #7074P2 or goat anti-mouse-HRP #7076S from Cell Signaling
Technology). WesternBright Sirius (Advansta #K-12043-D20) was used to detect target
proteins. Immunoblotting was performed with three biological replicates; protein
quantification was conducted using Image Lab Software (Bio-Rad).
Gene Expression Analysis
Isolation of mRNA using Invitrogen Cell to Ct kit (Life Technologies #4399002)
was used for the relative gene expression in HEK293T and U2OS following the
manufactures recommendations as previously described 65. Cells were plated in 96-well
plates and grown to 70% confluency before treatment with high glucose media. Cells
were then lysed and RT-PCR was performed to produce cDNA. Following cDNA
synthesis, qPCR was performed using the appropriate TaqMan gene expression primers
(XRCC1 Hs00959834_m1 FAM and IL-6 Hs00174131_m1 FAM) and TaqMan master
mix. Gene expression following IL-6 exposure was performed as previously described .
Briefly, cells were exposed to 50ng/mL IL-6 diluted in basal glucose media for 30 min, 1

53

h, and 4 h. Each gene expression experiment was performed in technical triplicates with
three biological replicates. Quantifications are represented as the mean of the three
biological replicates ± the standard error of the mean (SEM).
Chromatin Immunoprecipitation
Chromatin immunoprecipitation was performed as previously described 65.
Briefly, cells were plated in 150mm dishes and grown to 80% confluency. Cells were
crosslinked in 1% formaldehyde in 1X phosphate-buffered saline (PBS) at RT for 810min. Cells were then lysed in 1mL of Farnham lysis buffer (5mM HEPES pH 8.0,
85mM KCl, 0.5% NP-40) for 20min on ice, followed by centrifugation at 2000rpm to
pellet the lysed sample. The pellet was then re-suspended in RIPA buffer (50mM TrisHCl pH8, 150mM NaCl, 1% sodium deoxycholate, 1mM EDTA, 0.1% SDS, 1% Triton
X-100) for 20 min followed by sonication on ice at an amplitude of 10 on a Misonix S4000 with 15s on/50s off for a total time of 3.5 min for HEK293T and U2OS.
Immunoprecipitation was performed by incubating chromatin with anti-STAT3 diluted to
the manufactures’ recommendation (Cell Signaling Technology #9131S) and Protein A/G
magnetic beads (Thermo Fisher Scientific #88802) overnight at 4℃ with agitation on a
rotator. Magnetic bead conjugated chromatin was then washed with ice-cold LiCl wash
buffer (100mM Tris-HCl, 500mM LiCl, 1% NP-40, 1% Triton X-100) and TE buffer
(10mM Tris-HCl pH 7.5, 0.1mM EDTA). Proteinase K was added in ChIP elution buffer
(1% SDS, 0.1M NaHCO3) and incubated at 65℃ with agitation (950rpm) for 2h,
followed by proteinase K inactivation at 90℃ for 10 min. Isolated DNA was purified

54

using a PureLink PCR purification Kit (Life Technologies #K310002). XRCC1 Primers
were used as previously described 65.
Cell Growth Inhibition
Cells were plated at a density of 1X104 (HEK293T and U2OS) and 2X104 (MDA231) in 12 well-dishes and allowed 48 h to adhere. Cells were pretreated with high
glucose media prior to challenge with MMS. Cells were exposed to MMS for 1 h to 0,
0.5mM, 1mM, and 2mM concentrations, MMS was washed using 1XPBS, and fresh high
glucose media was added. Cells were allowed to recover for 5 days before being
trypsinized and resuspend in 1mL of PBS. Resuspended cells were counted using BioRad
TC-10 Automated Cell Counter. Cell counts were performed in triplicate normalized to
control wells for a total of three biological replicates. Values were plotted as mean ±
standard error of the mean (SEM)
Immunofluorescence
Immunofluorescence was performed as previously described 4. Briefly, cells were
plated on 60mm fluorodishes pretreated with 1 mL EmbryoMax 0.1% Gelatin Solution
(Millipore #ES-006-B) for 15-30 min at room tempreture. Cells were then plated at 2.5 X
104 per plate, allowing 24 h for cells to adhere. For HEK293T dishes were pretreated with
poly-L-lysine solution (Sigma #P4707-50mL) for 5 min and allowed to dry for 1 h before
cell plating. Cells were pretreated with high glucose-containing media for 4 h before
MMS exposure. Cells were exposed to MMS containing media for 1 h; cells were then
washed with 1X PBS and allowed to recover in fresh high glucose-containing media for 4
h and 24 h. Dishes were fixed using 3.7% formaldehyde in 1X PBS. Nuclear
permeabilization was accomplished by Permeabilization Buffer (Biotum #22016) 10min
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incubation at RT. Dishes were then blocked using 2% BSA in PBS for 30 min at RT.
Anti-Phospho-Histone H2AX (Ser139) (EMD Millipore #05-636) primary antibody
diluted in 2% BSA in PBS (1:400) was then incubated for 1 h at RT. Dishes were washed
with 1X PBS and Alexa Fluor™ 546 goat anti-mouse IgG (H+L) (Thermo Fisher
Scientific #A11003) secondary antibody was applied (1:2000) for 1 h. Nuclei were
stained with Hoechst 33342 (Thermo Scientific #62249) for 15 min at RT. Dishes were
mounted in Prolong™ Gold Antifade Reagent (Life Technologies #P36930).
Fluorescence images were acquired using a Nikon A1 scanning confocal microscope with
a Plan-Apochromat 20x/0.75 objective. To quantify the nuclear mean intensity, a region
of interest (ROI) generator was used to detect nuclei automatically in the DAPI channel.
The nuclear mean intensity of 𝛾H2AX was exported for analysis.
Single Cell Gel Electrophoresis (Comet Assay)
Cells were plated in 96-well plates at a density of 2.5 X 104 per well, allowing
24h for the cells to adhere. Cells were pre-treated with high glucose media 4h before
MMS exposure. IC25 concentrations were used to determine MMS dosing. Cells were
exposed to MMS containing media for 1h, then media was removed, and wells were
washed and replaced with fresh media. Following the indicated repair time, media was
removed and cells were trypsinized and resuspended in media. 100 𝜇L of resuspended
cells were then transferred to a CometChip® (Trevigen #4260-096-01). Following
overlay with 0.75% low melting temperature agarose, CometChip® were lysed overnight
at 4℃ in CometAssay lysis solution (Trevigen #4250-010-01). CometChip were then
incubated in alkaline solution (200mM NaOH, 1mM EDTA, 0.1% Triton 100X) for a
total of 40min at 4℃ . Electrophoresis was then performed for 50min at 22V. The
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alkaline solution was neutralized using 400mM Tris for a total of 30min at 4℃ followed
by 20mM Tris for a total of 30min at 4℃. CometChips® were then stained in SYBR™
Gold Nucleic Acid Gel Stain (Thermo Fisher Scientific #S11492) in 20mM Tris for 1h at
4℃ followed by a 30 min de-stain in 20mM Tris at 4℃. CometChips were imaged using
Celigo S Imaging Cytometer (Nexcelom Bioscience). Acquired images were analyzed
using Trevigen CometChip® analysis software.
Cell Adaptation
Basal glucose HEK293T and MDA-231 were grown in 25mM glucose-containing
DMEM, and U2OS were grown in 11mM containing RPMI. Adaptation to low glucose
(5mM) medium was accomplished in HEK239T and MDA-231 by briefly growing cells
in 17mM glucose-containing DMEM for 3 days, and the media was then changed to
10mM glucose-containing media for 1 week. Finally, cells were grown in low glucose
(5mM) DMEM for 1.5 weeks before being frozen and stored in liquid nitrogen. Similarly,
U2OS were adapted to low glucose containing RPMI by growing cells in 7mM
containing RPMI for 6 days before changing media to low glucose RPMI (5mM) for 1.5
weeks before being frozen and stored in liquid nitrogen. High glucose adaptation was
accomplished similarly. First, HEK293T and MDA-231 were grown in 27.5mM
containing DMEM for 1 week before being grown in high glucose (30mM) DMEM for
1.5 weeks. Following adaptation, cells were frozen and stored in liquid nitrogen. Finally,
U2OS cells were adapted to high glucose-containing RPMI (30mM) by briefly growing
cells in 20mM RPMI for 3 days followed by 1 week growth in 25mM RPMI. Finally,
cells were grown in high glucose RPMI (30mM) for 1.5 before being frozen and stored in
liquid nitrogen. HEK293T were adapted from passage 8 HEK293T, low glucose and high
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glucose HEK293T adapted cells were frozen at passage 12 and passage 11 respectively.
U2OS cells were adapted from passage 8 U2OS, low glucose and high glucose U2OS
were frozen at passage 10. MDA-231cells were adapted from passage 6 MDA-231, low
glucose MDA-231 were frozen at passage 11.
IL-6 ELISA Quantification
IL-6 media concentrations were measured using the Quantikine®ELISA Human
IL-6 kit (R&D systems #S6050) following the manufacturer's instructions. Briefly, cells
were plated in 150mm dishes and allowed to grow to 70—80% confluency before media
was collected. The ELISA was performed in technical triplicates with the mean ±
standard error of the mean (SEM) of three biological replicates presented.
Statistical Analysis
Assays were performed as three biological replications. One-way ANOVA and
means were compared with Dunnett’s post hoc analysis. Comparison groups are indicated
in graphs. All means are reported ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001,
**** p < 0.0001.

Results
Acute high glucose stimulates activation of STAT3 and XRCC1 expression
To examine the high glucose regulation of XRCC1, we exposed cells to 30mM
glucose for up to 24 h. We selected the osteosarcoma cell line U2OS, which has high
STAT3 activation, and HEK293T, which we showed previously has an inducible STAT3
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response 65. HEK293T cells were grown in 25mM glucose (BG) and had low XRCC1
expression (Figure 3.1A).

Figure 3.1. High glucose activates STAT3, subsequently increasing XRCC1
protein and gene expression : A) Representative western blot showing increased
XRCC1 following acute high glucose (30mM) for 1 h, 4 h, and 24 h in
HEK293T, including mean values for three repeats B) Quantification of
pSTAT3 protein expression in HEK293T normalized to control C)
Quantification of XRCC1 protein expression in HEK293T normalized to
control D) Quantification of XRCC1 gene expression in HEK293Tnormalized
to control E) Representative western blot showing increased XRCC1 following
acute high glucose (30mM) for 1 h, 4 h, and 24 h in U2OS, including mean
values for three repeats F) Quantification of pSTAT3 protein expression in
U2OS normalized to control G) Quantification of XRCC1 protein expression in
U2OS normalized to control H) Quantification of XRCC1 gene expression in
U2OS normalized to control * p < 0.05 ** p < 0.01,*** p< 0.001, **** p <
0.0001.
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The U2OS cells were grown in 11mM (BG) and had high initial XRCC1
expression (Figure 3.1E). Cells were then exposed to 30mM high glucose (HG) through
glucose addition to the basal medium for 1, 4, and 24 h. We observed an increase in
STAT3 activation as indicated by an increase in STAT3 phosphorylation at Y705 in the
HEK293T and U2OS cells (Figure 3.1A, B, E and F). A significant increase in XRCC1
protein and gene expression occurred in the HEK293T and U2OS cells (Figure 3.1C and
G). In HEK293T, XRCC1 gene expression increased at 1 and 4 h (2.2 ± 0.41 and 2.1 ±

Figure 3.2. 15𝜇M Alantolactone treatment reverses acute high glucose
increases in pSTAT3 and XRCC1 protein expression in HEK293T: A)
Representative western blot of Control (4 h), Control 4 h 30mM glucose,
DMSO 4 h 30mM, and 4 h 30mM glucose 4 h 15𝜇M alantolactone in
HEK293T B) Quantification of two western blots of pSTAT3
expression normalized to control (4 h) HEK293T C) Quantification of
two western blots of XRCC1 expression normalized to control (4 h)
HEK293T.
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0.30, respectively) following high glucose exposure, and the XRCC1 protein showed a
sustained increase at 4 h (2.3 ± 0.44) (Figure 3.1C and D).
For U2OS, XRCC1 protein expression peaked at 4 h and continued 24 h (3.5 ±
0.42 and 3.3 ± 0.59, respectively), and XRCC1 gene expression increased only at 1 h
after high glucose exposure (2.0 ± 0.20, Figure 3.1G and H).

Figure 3.3. Increased STAT3 occupancy of the XRCC1 promoter
following acute high glucose: A) ChIP analysis of STAT3 occupancy at
the XRCC1 promoter following acute high glucose (30mM) for 1 h, 4 h,
and 24 h in HEK293T normalized to respective IgG controls B) ChIP
analysis of STAT3 occupancy at the XRCC1 promoter following acute
high glucose (30mM) for 1 h, 4 h, and 24 h in U2OS normalized to
respective IgG control * p < 0.05, ** p < 0.01.

The role of STAT3 in this regulatory mechanism was further confirmed using the
STAT3 inhibitor alantolactone, which was shown to reduce XRCC1 expression following
4 h 15𝜇M alantolactone exposure (Figure 2.6). Alantolactone exposure in HEK293T
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resulted in attenuation of acute high glucose induced pSTAT3 and XRCC1 protein
expression (Figure 3.2A, B, and C)
STAT3 occupancy of the XRCC1 promoter increases following acute high glucose
exposure.
To confirm acute high glucose increases XRCC1 expression through a STAT3
transcription mechanism, we performed chromatin immunoprecipitation (ChIP) to follow
occupancy changes of STAT3 at the XRCC1 promoter with a 96 bp region (-452 to -358)
previously identified as a STAT3 binding site within the XRCC1 promoter 65. The
occupancy of STAT3 at the XRCC1 promoter was assessed in HEK293T and U2OS cells
following the 30mM glucose exposure for 1, 4, and 24 h (Figure 3.3A). In the HEK293T,
STAT3 occupancy of the XRCC1 promoter increased significantly 1 h following high
glucose (1.8 ± 0.12, enrichment compared to IgG control) before lowering at 4 and 24 h.
The U2OS cells showed a more sustained peak of STAT3 occupancy at the XRCC1
promoter 1 and 4 h following high glucose exposure (1.7 ± 0.12 and 1.7 ± 0.093,
enrichment compared to IgG control), returning to a level slightly below control at 24 h
(Figure 3.3B). These data indicated STAT3 activation following acute high glucose
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exposure resulted in increased XRCC1 gene and protein expression through increased
STAT3 occupancy at the XRCC1 promoter.

Figure 3.4. Increased MMS survival following acute high glucose: A) Cell
counting survival curve following dosing of MMS in HEK293T, HEK293T
30mM high glucose for 4 h followed by continuous high glucose exposure,
mean survival (%) and SEM (%) normalized to 0mM control HEK293T B)
Cell counting survival curve following dosing of MMS in U2OS, U2OS
30mM high glucose for 4 h followed by continuous high glucose exposure,
mean survival (%) and SEM (%) normalized to 0mM control U2OS* p < 0.05,
** p < 0.01, **** p < 0.0001.

High glucose induced XRCC1 promotes cell survival through increased DNA repair
Increased XRCC1 expression is associated with increased survival against
genotoxic stress 78. We next examined the extent that high glucose induced XRCC1
expression altered cell survival after exposure to the classic BER alkylating agent MMS.
Cytotoxicity of MMS was assessed by cell growth inhibition. Cells were treated with
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high glucose for 4 h before MMS exposure to ensure XRCC1 expression was increased
(Figure 3.1).

Figure 3.5. Doubling time for BG HEK293T and BG U2OS continuous
exposure to HG A) Proliferation of HEK293T BG and continuous HG
exposure HEK293T values presented as cell count % of control B)
Proliferation of BG U2OS and continuous HG exposure U2OS values
presented as cell count % control.

Cells were then exposed to increasing concentrations of MMS for 1 h in high
glucose and sustained in high glucose after exposure (Figure 3.4). To confirm the
changes in survival were not due to increased proliferation, the doubling time for acute
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high glucose exposure was assessed out to 72 h, with only a slight, non-significant,
increase in basal glucose HEK293T proliferation occurring compared to acute HG
HEK293T (Figure 3.5).

Figure 3.6. Reduced gamma-H2AX indicates increased repair of MMS
induced damage following acute high glucose : A) Representative
immunofluorescence images of HEK293T and acute HG HEK93T 4 h and
24 h post 1mM MMS B) Quantification of nuclear mean intensity of
immunofluorescence images of HEK293T and acute HG HEK293T C)
Representative immunofluorescence images of U2OS and acute HG U2OS
4 h and 24 h post 2mM MMS D) Quantification of nuclear mean intensity
of immunofluorescence images of U2OS and acute HG U2OS * p < 0.05
** p < 0.01,*** p< 0.001, **** p < 0.0001.
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Figure 3.7. Comet assay indicates increased DNA repair following
acute high glucose: A) Timeline of MMS dosing for the comet assay B)
Comet assay, the % DNA in the comet tail in HEK293T and acute HG
HEK293T 0h, 1, 4, and 24 h post 1mM MMS exposure C) Comet
assay, the % DNA in the comet tail in U2OS and acute HG U2OS 0, 1,
4, and 24 h post 2mM MMS exposure * p < 0.05 ** p < 0.01,*** p<
0.001, **** p < 0.0001.

To confirm the increased survival is due to a change in DNA repair, we examined
changes in DNA damage after MMS challenge in the basal and acute high glucose.
HEK293T and U2OS cells were dosed with IC25 doses of MMS 1 and 2mM, respectively
(Figure 3.4). Phosphorylation of H2AX at the serine 139 residue (γ-H2AX) was used to
assess the formation of single and double strand breaks following exposure to MMS. In
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the HEK293T, a significant reduction in γ-H2AX nuclear signal was seen 24 h postMMS exposure in the high glucose cells compared to their BG controls (Figure 3.6A and
B). The U2OS cells saw a more significant reduction in γ-H2AX nuclear signal at 4 and
24 h post-MMS exposure than the BG controls (Figure 3.6C and D).
Finally, we examined repair dynamics using alkaline single cell gel
electrophoresis (comet assay) under basal and acute high glucose conditions. DNA repair
was assessed by monitoring the percentage of DNA in the comet tail in untreated cells
and after 1 h exposure to 1 or 2mM MMS (IC25) for 0, 1, 4, and 24 h of repair time in the
HEK293T and U2OS, respectively (Figure 3.7A). Increased DNA in the comet tail
indicates increased DNA strand breaks and alkaline labile sites. Following MMS
exposure, the acute high glucose pretreated HEK293T showed an increase in DNA repair
as indicated by the reduction of the percentage of DNA in the comet tail at 24 h repair
time (17% ± 2.2%) following MMS exposure compared to HEK293T BG control (36%
± 6.3% ) with similar increases in repair occurring in acture high glucose exposed U2OS
at 24 h repair time following MMS exposure (37% ± 2.5) compared to U2OS BG control
(17% ± 5.7%) (Figure 3.7B and C).
Adaptive changes in glucose concentration alter STAT3 activation, XRCC1
expression, and STAT3 occupancy of the XRCC1 promoter
Next, we wanted to determine if adaptive changes due to long-term glucose
concentration changes would drive dysregulation of XRCC1 in HEK293T and U2OS
cells, similar to what we have previously reported in TNBC cells 65. HEK293T and U2OS
were adapted to low, physiologically relevant glucose (LG, 5mM), basal medium glucose
(BG, 25mM for HEK293T and 11mM for U2OS), and high glucose (HG, 30mM)

67

medium by passaging the cells for 1.5 weeks in increasing mixtures of glucose followed
by growth in final desired glucose concentrations for at least 2 weeks before analysis 84.

Figure 3.8. Adaptive alterations in XRCC1 expression following adaptation to glucose
concentrations A) Representative western blot of pSTAT3 and XRCC1 in HEK293T
adapted cell lines Low Glucose 5mM (LG), Basal Glucose 25mM (BG), and High
Glucose 30mM (HG) including mean values for three repeats B) Quantification of
pSTAT3 protein expression in HEK293T adapted cell lines LG, BG, and HG normalized
to BG C) Quantification of XRCC1 protein expression in HEK293T adapted cell lines
LG, BG, and HG normalized to BG D) ChIP analysis of STAT3 occupancy of the XRCC1
promoter in adapted HEK293T cell lines LG, NG, and HG normalized to respective IgG
controls E) Representative western blot of pSTAT3 and XRCC1 in U2OS adapted cell
lines Low Glucose 5mM (LG), Basal Glucose 11mM (BG), and High Glucose 30mM
(HG) including mean values for three repeats F) Quantification of pSTAT3 protein
expression in U2OS adapted cell lines LG, BG, and HG normalized to BG G)
Quantification of XRCC1 protein expression in U2OS adapted cell lines LG, BG, and HG
normalized to BG H) ChIP analysis of STAT3 occupancy of the XRCC1 promoter in
adapted U2OS cell lines LG, BG, and HG normalized to respective IgG controls * p <
0.05 ** p < 0.01,*** p< 0.001, **** p < 0.0001.

68

Figure 3.9. MDA-231 have reduced responsiveness to alterations in
glucose concentrations: A) Representative western blot of pSTAT3
and XRCC1 in MDA-231 adapted cell lines Low Glucose 5mM (LG)
and Basal Glucose 25mM (BG) B) Quantification of XRCC1 protein
expression in MDA-231 adapted cell lines LG and BG C)
Quantification of pSTAT3 protein expression in MDA-231 adapted
cell lines LG and BG D) ChIP analysis of STAT3 occupancy of the
XRCC1 promoter in adapted MDA-231 cell lines LG and BG
normalized to respective IgG controls * p < 0.05 ** p < 0.01,*** p<
0.001, **** p < 0.0001.

Reduced STAT3 activation (lower pSTAT3) was seen for LG HEK293T (0.28 ±
0.79) and U2OS (0.34± 0.098) compared to their respective BG controls (Figure 3.8B
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and F). Sustained STAT3 activation occurred in HG HEK293T (2.4 ± 0.16) and U2OS
(3.9 ± 0.10) compared to BG controls (Figure 3.8B and F). Sustained alterations in
STAT3 activation resulted in dysregulation of XRCC1 protein expression changes with
reduced XRCC1 (0.25 ± 0.04) in LG HEK293T and increased XRCC1 (1.9 ± 0.34) in
HG HEK293T compared to BG HEK293T controls (Figure 3.8C and G). Similar
alterations occurred in U2OS with lower XRCC1 protein expression (0.29 ± 0.17) in LG
U2OS and increased XRCC1 expression (2.4 ± 0.21) in HG U2OS than BG U2OS
controls (Figure 3.7C and G). We also confirmed STAT3 occupancy at the XRCC1
promoter using ChIP. Decreases in STAT3 activation in LG HEK293T and U2OS
correlated with a reduction below BG control of STAT3 enrichment at the XRCC1
promoter (0.98 ± 0.30 and 0.93 ± 0.19, compared to IgG controls, respectively) (Figure
3.8D and H). Sustained activation of STAT3 in HG HEK293T and HG U2OS correlated
with an increase of enrichment of STAT3 at the XRCC1 promoter (2.9 ± 0.34 and 2.3 ±
0.30, compared to IgG control respectively) compared to BG HEK293T and U2OS (1.5
± 0.16 and 1.3 ± 0.40, respectively) (Figure 3.8D and H).
Low glucose adaptation of the TNBC cell line MDA-231 only partially reduces
STAT3 occupancy of the XRCC1 promoter
We previously reported that STAT3 plays a major role in regulating XRCC1 in
TNBC cell lines, including the MDA-231 65. Given the constitutive activation of STAT3
in MDA-231, we next wanted to see if glucose restriction altered the activation of STAT3
and regulation of XRCC1 in the MDA-231. MDA-231 cells were adapted to low glucosecontaining media (5mM) as described above. Previous experiments were conducted in
25mM glucose (BG). Following the adaptation to LG, MDA-231 showed only a slight
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reduction in the activation of STAT3 (0.71 ± 0.08), which resulted in a slight decrease of
XRCC1 protein expression (0.65 ± 0.12) compared to the BG MDA-231 control (Figure
3.9A and B). Similarly, LG only slightly reduced the occupancy of STAT3 at the XRCC1
promoter (1.8 ± 0.066) compared to BG control MDA-231 (2.4 ± 0.11), and both the LG
and BG MDA-231 have a higher STAT3 occupancy at the promoter than that seen for
BG HEK293T and U2OS (Figure 3.9D).
IL-6 expression and stimulation increases pSTAT3 and XRCC1 in HEK293T and
U2OS
In humans, hyperglycemia increases inflammatory cytokines, like IL-6, a known
activator of STAT3 94. Increasing glucose concentrations in cell culture medium has also
been shown to increase IL-6 production and secretion across various cell types 92,93,95,96.
We previously demonstrated that exogenous addition of IL-6 activated STAT3, increased
the expression of XRCC1, and increased the occupancy of STAT3 within
the XRCC1 promoter in HEK293T and MDA-231 cells 65. With the variations in
responses between the HEK293T, MDA-231, and U2OS cells, we examined the
exogenous IL-6 and IL-6R𝛼 levels and the effects of glucose stimulation and restriction.
We first measured IL-6 concentrations in the HEK293T, MDA-231, and U2OS glucoseadapted cell lines (Figure 3.10A, B, and C). In the BG medium, HEK293T showed low
IL-6 levels in the spent medium, while U2OS and MDA-231 showed high IL-6
concentrations in the spent medium. Changing the glucose concentrations induced IL-6
release into the spent medium for U2OS cells, but only slight increases were observed in
HEK293T and MDA-231. Reducing the glucose in HEK293T and U2OS also reduced
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the IL-6 released into the medium (Figure 3.10A and C). We also examine the expression
of IL-6R𝛼 under different glucose conditions across the cell lines (Figure 3.10D).

Figure 3.10. Expression of IL-6 and IL-6R𝛼 modulate the STAT3 activation
and subsequent XRCC1 expression : A) Quantification of IL-6 concentration in
the media of adapted HEK293T cell lines B) Quantification of IL-6
concentration in the media of adapted MDA-231 cell lines C) Quantification of
IL-6 concentration in the media of adapted U2OS cell lines D) Representative
western blot of pSTAT3, STAT3, IL-6R𝛼 and XRCC1 in HEK293T, MDA-231,
and U2OS adapted cell line * p < 0.05 ** p < 0.01,*** p< 0.001, **** p <
0.0001.
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Figure 3.11. Acute IL-6 exposure in BG U2OS A) Representative western
blot for pSTAT3, STAT3, and XRCC1 following 50ng/mL IL-6 exposure
for 30 min, 1 h, and 4 h, tubulin as the loading control with mean values
for three repeats B) Quantification of pSTAT3 protein following 50ng/mL
of IL-6 exposure for 30 min, 1 h, and 4 h C) Quantification of XRCC1
protein expression following 50ng/mL of IL-6 exposure for 30 min, 1 h,
and 4 h D) Quantification of XRCC1 gene expression following 50ng/mL
of IL-6 exposure for 30 min, 1 h, and 4 h E) ChIP analysis of STAT3
occupancy of the XRCC1 promoter following 50ng/mL of IL-6 exposure
for 4 h *p<0.5, **p<0.01

IL-6 binding to IL-6R𝛼 activates STAT3 through several signaling mechanisms,
including interactions with EGFR and JAK 91,97. We observed high levels of IL-6R𝛼 in
the HEK293T, and the receptor levels fluctuated with glucose concentrations. The high
levels of IL-6R𝛼 in the HEK293T made the immunoblot detection of the MDA-231 and
U2OS more difficult.To investigate the links between glucose and IL-6 stimulation of
STAT3, we then examined the activation of STAT3 relative to IL-6 protein and gene
expression in HEK293T (Figure 3.10A, B and C) and U2OS (Figure 3.10D, E, and F).
We verified that IL-6 stimulated pSTAT3 and subsequently increased XRCC1 expression
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in BG U2OS (Figure 3.11A, B, C), which we previously reported in HEK293T and
MDA-231 65. Following 50ng/mL IL-6 exposure, increased STAT3 activation and
XRCC1 protein and gene expression occurred at 1 h in the U2OS (3.5±0.42 and
1.7±0.091, respectively) (Figure 3.12A, B, C, and D).
Using ChIP, an increase in STAT3 occupancy at the XRCC1 promoter verified
STAT3 regulation of XRCC1 following IL-6 exposure in U2OS (2.4±0.27 enrichment
following IL-6 exposure compared to 1.3±0.03 enrichment for control U2OS) (Figure
3.10E). These results are consistent with the previous findings in HEK293T with
increased inducibility following IL-6 exposure in the U2OS but differ from the
constitutively active MDA-231, which lack inducibility following IL-6 exposure (Figure
2.8 and 2.12). To investigate the links between glucose and IL-6 stimulation of STAT3,
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we then examined activation of STAT3 relative to IL-6 protein and gene expression in
HEK293T (Figure 3.11A, B and C) and U2OS (Figure 3.11D, E, and F)

Figure 3.12. Acute hyperglycemia stimulates IL-6 protein and gene
expression: A) Representative western blot showing increased pSTAT3
and IL-6 following acute hyperglycemia 30mM for 1 h, 4 h, and 24 h in
HEK293T B) Quantification of IL-6 protein expression in HEK293T
normalized to control C) Quantification of IL-6 gene expression in
HEK293T normalized to control D) Representative western blot
showing increased pSTAT3 and IL-6 following acute hyperglycemia
30mM for 1 h, 4 h, and 24 h in U2OS E) Quantification of IL-6 protein
expression in U2OS normalized to control F) Quantification of IL-6
gene expression in U2OS normalized to control; Blots from this figure
were used in Figure 3.1 as well to allow comparison * p < 0.05 ** p <
0.01,*** p< 0.001, **** p < 0.0001.
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Figure 3.13. XRCC1 inducibility determines response to MMS: A) Cell
counting survival curve following dosing of MMS in MDA-231, MDA-231
were dosed with 50ng/mL IL-6 for 30 min followed by continuous IL-6
exposure, mean survival (%) and SEM (%) normalized to control MDA-231
C) Cell counting survival curve following dosing of MMS in HEK293T,
HEK293T were dosed with 50ng/mL IL-6 for 30 min followed by continuous
IL-6 exposure, mean survival (%) and SEM (%) normalized to control
HEK293T D) Cell counting survival curve following dosing of MMS in
U2OS, U2OS were pre-treated with 50ng/mL IL-6 for 30 min followed by
continuous IL-6 exposure, mean survival (%) and SEM (%) normalized to
control U2OS.
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Next, we examined the sensitivity of the cell lines to MMS following 30 min
50ng/mL IL-6 exposure before applying challenge with MMS followed by continuous
exposure to IL-6. Increased resistance to MMS occurred following acute IL-6 exposure
with the largest increase in resistance occurring in the HEK293T (40±7.1% survival for
control compared to 76±6.1% IL-6, respectively, following 0.5mM MMS), a moderate
response in U2OS (65±4.5% survival for control compared to and 99±10% for IL-6,
following 0.5mM MMS), and a limited response in MDA-231 (31±7.7% survival for
control compared to 47±8.4% for IL-6, following 0.5mM MMS) (Figure 3.12).
High EGFR expression in MDA-231 mitigates glucose-driven changes in pSTAT3

Figure 3.14. High expression of EGFR measures response in MDA-231:
A) Representative western blot of pEGFR (Y1068) and EGFR in
HEK293T, MDA-231, and U2OS adapted cell lines B) Comet assay in
LG and BG MDA-231 following 1mM MMS exposure * p < 0.05 ** p <
0.01,*** p< 0.001, **** p < 0.0001.

The differences observed between MDA-231 and the HEK293T and U2OS cells
suggest that another upstream regulator of STAT3 is involved. We previously reported
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increases in STAT3 activation and XRCC1 expression in MDA-231 cells exposed to
EGF 65. With minimal IL-6 responses in MDA-231, we examined EGFR expression and
activation across the cell line panel (Figure 3.14A). Immunoblotting revealed increased
EGFR expression in MDA-231, moderate EGFR expression in U2OS, and non-detectable
EGFR expression in HEK293T (Figure 3.14A). High activation and expression of EGFR
MDA-231 may be responsible for the observed constitutive activation of STAT3. Even
under low glucose, the MDA-231 lack a significant reduction in STAT3 activation (0.71
± 0.08) and occupancy at the XRCC1 promoter (1.8 ± 0.07, compared to IgG controls)
compared to HEK293T and U2OS (0.98 ± 0.30 and 0.93 ± 0.19, compared to IgG
controls, respectively) (Figure 3.7 and 3.8). We confirmed this lack of change in DNA
repair through a comet assay with LG and BG MDA-231 adapted cell lines following
1mM exposure to MMS. The comet assay revealed no significant change in DNA repair
following LG adaptation (Figure 3.14B), consistent with the maintenance of STAT3
driven expression of XRCC1 (Figure 3.9).

Discussion

We have previously reported that STAT3 drives the dysregulation of XRCC1 in
TNBC while serving as an inducible transcription factor in the non-tumorigenic
HEK293T 65. Here, we show high glucose drives STAT3 activation, increasing the
expression of XRCC1. Acute high glucose (30mM) exposures increased STAT3
activation and XRCC1 protein and gene expression in the non-tumorigenic HEK293T
and osteosarcoma U2OS cell lines. The XRCC1 gene and protein increases are linked to
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the increased occupancy of STAT3 at the XRCC1 gene. Further, acute high glucose
induced XRCC1 increased survival to DNA damage and improved repair dynamics in
HEK293T and U2OS cells exposed to MMS.
If unrepaired, single-strand breaks can increase mutations and chromosomal
aberrations, promoting carcinogenesis. Exogenous and endogenous agents can induce the
expression of DNA repair proteins to respond to increased lesions and breaks to maintain
genomic fidelity. The XRCC1 regulator E2F1 behaves in this manner, increasing the
expression of XRCC1 after exogenous insult with MMS to increase repair and maintain
genomic fidelity 14. Therefore, high DNA repair protein expression serves as a safeguard
to carcinogenesis. However, DNA repair is a double-edged sword. The DNA itself is
damaged during repair, and too much repair can also be lethal to the cell. Therefore,
DNA repair proteins are tightly regulated to prevent extraneous repair. Again, Sp1 and
ATM are examples of how this process works for XRCC1. If the repair load becomes too
high, ATM phosphorylates Sp1, halting Sp1 regulation of XRCC1 expression in order to
prepare the cell for apoptosis 13. In cancers, the processes by which DNA repair proteins
become dysregulated are largely unknown. Overexpression of BER proteins has been
correlated with a hypermutability phenotype, which promotes cancer formation 98-100.
Overexpression of BER proteins is also correlated with chemotherapy and radiation
therapy resistance, confirming that an imbalance of DNA repair proteins provides an
advantage to cancer cells 30-32,63,78.
We first examined STAT3 regulation of XRCC1 in TNBC cell lines where
STAT3 had become constitutively active, but the driving factors leading to dysregulation
were not examined. Here, we confirmed that glucose challenge activated STAT3 and
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drove XRCC1 expression in cells without constitutively active STAT3. These data
demonstrate that STAT3 induces XRCC1 expression in response to exogenous challenges
and that the effects are transient and reduce when cell equilibrium is reacquired. The
temporal increase and decrease in STAT3 activation and XRCC1 expression in the
HEK293T and U2OS cells demonstrate this inducible regulation (Figure 3.1). However,
when we adapted HEK293T and U2OS cells to high glucose continuously, we saw a
sustained activation of STAT3 and continued expression of XRCC1, which suggests that
continuous glucose exposure can lead to increased XRCC1 protein levels. Although
higher glucose concentrations were not tested, a leveling-off of glucose transport would
be expected at concentrations higher than 30mM. Previous reports have shown a plateau
of cytosolic glucose concentrations following exposure to 25mM and 30mM glucose
concentrations in HEK293T co-expressing GLUT1 and GLUT2 glucose transporters 101.
Additionally, at higher glucose concentrations, a reduction of high-affinity glucose
transporter, GLUT1 protein expression and increased low-affinity glucose transporter,
GLUT2, protein expression has been observed 102. Thus, at high glucose concentrations
above 30mM, minimal changes in transport would be expected. When studying changes
in glucose concentrations, osmolarity changes are sometimes observed, resulting in cell
swelling and potentially death to the cell. Mannitol is often used to control for potential
differences in osmolarity between different glucose concentrations. However, mannitol
was not used here due to its role in ROS scavenging 103-105. It has been previously
reported that ROS production following high glucose exposure promotes the production
of IL-6 through activation of NF𝜅B 106. Thus, introduction of a ROS scavenger could
attenuate STAT3 activation following high glucose exposure. Previous reports
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investigating changes in UV-associated DNA repair in low and high glucose conditions
used mannitol as an osmolarity control and did not observe any changes in repair 87.
Future work focusing on the adaptive transcriptional gene regulatory mechanism
following continous glucose alterations is needed. These studies could provide a greater
understanding of how glucose adaption alters gene regulation of XRCC1, which has been
previously reported in nucleotide excision repair proteins following continous genotoxic
exposure 17.
Here, we studied the DNA repair changes associated with increased XRCC1
expression following acute high glucose exposure. There is an advantage to increased
XRCC1 expression shown through the improved cell survival and DNA repair after
MMS challenge (Figures 3.5 and 3.6). DNA damaging agents are commonly used in
cancer therapy, and altered expression of XRCC1 has been found to modulate responses
in numerous cancers 28,31,32,34,63,78,107. STAT3 was not previously identified as a regulator
of XRCC1, but the data here demonstrate that STAT3 activation promotes resilience to
DNA damage, which likely contributes to chemoresistance or even radiotherapy
resistance in cancer cells.
Critically, these effects could be reversed when activated STAT3 is lowered
through glucose restriction. Low glucose media (5mM) reduced STAT3 activation in
HEK293T and U2OS, reducing the STAT3 enrichment at the XRCC1 promoter as well as
XRCC1 gene and protein expression compared to higher glucose media compositions.
However, in MDA-231, which have constitutively activated STAT3, low glucose
adaptation resulted in a less significant reduction of STAT3 activation (Figure 3.8),
STAT3 enrichment at the XRCC1 promoter, and XRCC1 protein expression. When we
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examined the upstream regulators of STAT3 activation in these cell lines, the MDA-231
cells, unlike the U2OS and HEK293T cells, also had highly activated EGFR, which likely
maintains the STAT3 activation and elevated XRCC1 expression.
In looking at other upstream regulators of STAT3 activation, we noted clear
differences in the expression of IL-6R𝛼 and the stimulation of IL-6 release in these cells
that correspond to increasing glucose concentration. It appears the increased expression
of IL-6R𝛼 has a major role in the inducibility of the non-tumorigenic HEK293T, which
we reported previously with IL-6 and here with high glucose (Figure 3.9) 65. Together
these findings suggest that multiple mechanisms drive the activation of STAT3 within
cancer cells, but once STAT3 is activated, XRCC1 gene and protein levels will be
elevated and impact the cells' responses to DNA damage.
Chronic inflammation, increased inflammatory cytokine signaling, and increased
mitogenic signaling are all common in cancer. Here, we show that STAT3 activation
induces XRCC1 expression, and continued activation of STAT3 drives BER
dysregulation in non-tumorigenic HEK293T and tumorigenic U2OS. Additionally, the
induction of this response following exogenous exposures alters the response to the DNA
damaging agent MMS, with the most inducible HEK293T having the highest increase in
resistance to MMS following STAT3 activation induced by exposure to high glucose and
IL-6 (30 ± 1.8% survival for HEK293T compared to 65 ± 6.7% survival for HG and 74
± 8.8% survival for IL-6 following 1mM MMS exposure) (Figure 3.12). We have also
determined that these effects can be mitigated with glucose restriction if other drivers of
dysregulated STAT3 activation are absent. These findings suggest that the degree to
which these effects can be reversed through therapeutic intervention upstream of STAT3
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would depend highly on the signaling nodes used to activate STAT3. Additionally, these
findings indicate an inverse relationship between IL-6 concentrations and IL-6R𝛼 in
HEK293T (low and high, respectively), MDA-231 (moderate and low, respectively) and
U2OS (high and moderate, respectively), and a direct relationship between IL-6R𝛼
expression, inducibility of the cell lines, and resistance to DNA damaging agents in
HEK293T (high), MDA-231 (low), and U2OS (moderate). A better therapeutic strategy
for reversing the dysregulation of BER observed here would be targeting STAT3, which
we previously demonstrated with alanolactone and shRNA in TNBC cell lines and here
with alantolactone in HEK293T following acute high glucose exposure (Figure 3.2) 65.
In sum, this study identified a new transcriptional regulation mechanism for
XRCC1, providing a novel link between exogenous exposures, activation of STAT3, and
DNA repair. This regulatory mechanism could have major implications in promoting
genomic instability and modulating therapeutic response, both critical in the formation
and progression of cancer. This work also suggests that transcriptional regulation of BER
proteins is highly responsive to exogenous and endogenous changes. Much more work is
needed to understand known regulators such as E2F1 and STAT3 and the stimulating
conditions that induce transcription through currently unknown regulators. Expression of
BER factors, including PARP1, POL β, and XRCC1, are dysregulated in various cancers
and associated with poor survival outcomes, and we need a better understanding of the
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regulation landscape driving these changes to identify therapeutic targets and improve
patient survival.
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CHAPTER IV: STAT3 ROLE IN THE REGULATION OF BER PROTEINS
POLYMERASE BETA AND POLY(ADP)RIBOSE POLYMERASE

Introduction
Along with XRCC1, POL 𝛽 and PARP1 serve as critical DNA repair proteins in
the BER pathway (Figure 1.1). Following the formation of SSBs, PARP1 binds the site of
damage and undergoes auto modification in the form of PARylation, the covalent linkage
of ADP-ribose polymers to proteins. This PARylation is critical in the recruitment and
binding of other BER proteins, including XRCC1. POL 𝛽 is the primary polymerase
responsible for DNA synthesis during the BER process. Key interactions between the Nterminal domain of XRCC1 and the thumb and/or palm domain of POL 𝛽 help facilitate
its enzymatic activity 9,108.
In cancers, POL 𝛽 protein variants occur in 30% of human tumors. The K289M
variant has been shown to have reduced polymerase activity and is tightly associated with
colon cancers 11. Another POL 𝛽 variant, P242R, increases resistance to cisplatin through
increased translesion synthesis 109. Overexpression of POL 𝛽 has been observed in a
number of cancer associated tissue samples including breast, colon, and prostate 35. POL
𝛽 overexpression also occurs in breast, ovarian, and colon cancer cell lines 35,110.
Alterations in POL 𝛽 expression are linked to genomic instability, a hallmark of cancer,
with overexpression of POL 𝛽 in CHO cells resulting in a 3-8-fold increase in mutational
rates and increased frameshift mutations in Ha cells derived from B-Cell lymphoma 98,111.
Increased expression of POL 𝛽 increases resistance to DNA damaging agents, including
MMS 107. Disruption of POL 𝛽 function results in increased platinum-based

85

chemotherapeutic sensitivity 29. Despite these links to BER dysfunction and
chemoresistance, no transcription factors have been implicated in the dysregulation of
POL 𝛽 that is seen in TNBC. Several transcription factors, Sp1, NF𝑘B, TEIF, and
CREB-1 (Figure 1.3), have been identified to regulate POL 𝛽 , but there are still gaps in
our understanding of its transcriptional regulation 12.
PARP1 overexpression results in higher tumor grade and poorer outcomes in
breast cancer tumors and is more closely associated with TNBC 112. Overexpression of
PARP1 has been documented in tissues isolated from breast, uterine, ovarian, skin, and
lung cancers 113. Increased PARP1 expression resulted in resistance to the PARP inhibitor
Olaparib in human breast cancer cell lines 114. Inhibition of PARP1 increases
sensitization of cancer cells to therapeutics, including cisplatin, carboplatin,
camptothecin, temozolomide, and ionizing radiation 115-118. Dysregulation of PARP1
plays a critical role in therapeutic responses in multiple cancers. Additionally, PARP1
overexpression has been shown to sensitize cells to DNA damaging agents, including
alkylating agents and 𝛾-radiation 119,120. This suggests an optimal activity and expression
of PARP1. A PARP1 SNP, V762A, which has reduced ADP-ribosylation activity, has
been correlated within increased risk of prostate and gastrointestinal cancers 121,122. Thus,
dysregulation of PARP1 and PARP1 activity could play a role in both therapeutic
resistance and genomic instability, promoting the growth and formation of cancer.
However, regulation of PARP1 still remains understudied with only five transcription
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factors regulating its expression - Sp1, Sp3, YY-1, NF1, and ETS, none of which have
been associated with PARP1 dysregulation in TNBC (Figure 1.4) 12.
We have identified dysregulation of POL 𝛽 and PARP1 in TNBC cell lines, and
this dysregulation contributes to altered response to DNA damaging chemotherapeutics.
Further understanding of the transcriptional regulation of POL 𝛽 and PARP1 could
provide insight into the dysregulation of these proteins in TNBC.

Materials and Methods
Chemicals
Alantolactone was acquired from Selleckchem (Selleckchem #S8318) and
resuspended in anhydrous DMSO to a concentration of 15mM.
Cell Culture
MDA-MB-231(MDA-231), MDA-MB-468 (MDA-468), and HEK293T were
purchased from the American Type Culture Collection (ATCC HTB-26, HTB-132, and
CRL-3216, respectively; Manassas, VA, USA) within the last 24 months and passaged <
15 times for all experiments. Cells were tested biweekly during experiments for
mycoplasma contamination using the Lonza MycoAlert® (Lonza #LT07-318). MDA-231
and MDA-468 cells were grown in DMEM High Glucose + GlutaMAX™ (Life
Technologies, Carlsbad, CA, USA, #10566016) and supplemented with 1% sodium
pyruvate (Life Technologies, #11360070) and 10% FBS (Premium Select, R&D systems,
Minneapolis, MN, USA). HEK293T cells were grown in DMEM High Glucose + LGlutamine (HyClone, Logan, UT, USA, # SH30022.01) and supplemented with 1%
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sodium pyruvate (Life Technologies #11360070) and 10% FBS. Cells were maintained in
a humidified 37 °C incubator with 5% carbon dioxide.
In Silico Transcription Factor Search
Potential transcription factor targets for the POLB promoter were identified using
multiple in silico softwares. First, an ENCODE database search was performed to
identify transcription factors binding the promoters of interest. IgV browser was used to
define potential transcription factor binding sites further.
Chromatin Immunoprecipitation
MDA-231, MDA-468, and HEK293T cells were grown to confluency in a
150mm dish. The cells were crosslinked by the addition of 1% formaldehyde in DMEM
with gentle rocking at room temperature (RT ~23 °C) for 8–10 min. Then, 0.1 M glycine
was added for 5 min at RT to quench the formaldehyde. The cells were washed with cold
1× phosphate-buffered saline (PBS) and subsequently lysed with 1 mL of farnham lysis
buffer (5 mM HEPES pH 8.0, 85 mM KCl. 0.5% NP-40) for 20 min on ice, then pelleted
by centrifugation at 2000 rpm and resuspended in RIPA buffer (50mM Tris-HCl pH 8,
150mM NaCl, 1% sodium deoxycholate, 1mM EDTA, 0.1% SDS, 1% Triton X-100) for
20 min. Isolated chromatin was then sonicated on ice at an amplitude of 12 on a Misonix
S-4000 with 15 s on/50 s off for a total process time of 2.5 min for MDA-231 and MDA468 and an amplitude of 10 on a Misonix S-4000 with 15 s on/50 s off for a total process
time of 3.5 min for HEK293T. Chromatin was incubated overnight at 4 °C on a rotator
using an anti-STAT3 antibody diluted to manufacturers’ recommendations for chromatin
immunoprecipitation (Cell Signaling Technology, Danvers, MA, USA #9131S), an antiSp1 antibody (Abcam Cambridge, MA, USA #ab13370) diluted 1:100 as a positive
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control, a mouse IgG isotype control (Cell Signaling Technology #5415S) and with
Protein A/G magnetic beads (Thermo Fisher Scientific #88802). Magnetic beads were
washed with cold LiCl wash buffer (100 mM Tris-HCl, 500 mM LiCl, 1% NP-40, 1%
Triton X-100) and TE Buffer (10mM Tris-HCl pH 7.5, 0.1mM EDTA). Proteinase K
(VWR Life Science Radnor, PA, USA # E195-5ML) was then added with ChIP Elution
Buffer (1% SDS, 0.1 M NaHCO3) and incubated at 65 °C 950 rpm for 2 h. Proteinase K
was then inactivated at 90 °C for 10 min. DNA was purified using a PureLink PCR
Purification Kit (Life Technologies #K310002 kit). An IgV browser was used to design
primers examining the occupancy across the POLB and PARP1 promoter (Appendix C).
Western Blotting
Briefly, the cells were grown in 150mm dishes and cultured to 70–80%
confluence. Cells were rinsed with PBS, scraped, stored overnight at −80 °C, then lysed.
Protein content was quantified using a Bradford assay. Then, 20 µg of lysate was
separated on 7.5% or 4–15% SDS Page gel (Bio-Rad #s, 4561025 and 4561084) and
transferred to a nitrocellulose membrane. Membranes were blocked in 5% non-fat dry
milk in Tris-buffered saline (VWR #J640-4L) containing 0.1% Tween20 (Thermo Fisher
Scientific #BP337, TBS-T) and raised against the following primary antibodies: POL 𝛽
(1:1000 #ab175197) from Abcam (Boston, MA, USA); PARP1 (1:1000,556494 from BD
Pharmigen (San Diego, CA, USA); STAT3 (1:1000, #9139) and pSTAT3 Y705 (1:500,
#9131) from Cell Signaling Technology, Inc.; and α-tubulin (1:5000, #T9026) from
Millipore Sigma (St. Louis, MO, USA). The blots were incubated with either of the
horseradish peroxidase (HRP)-labeled secondary antibodies: goat anti-rabbit-HRP or goat
anti-mouse-HRP (#7074P2 and #7076S respectively) from Cell Signaling Technology,
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Inc. HRP antibody target proteins were detected by incubating with WesternBright Sirius
(Advansta San Jose, CA, USA #K-12043-D20). All immunoblotting was conducted with
three biological replicates. Where indicated, protein quantification was conducted with
Image Lab Software (Bio-Rad, Hercules, CA, USA). Band intensity was normalized to
loading controls and averaged over the three biological replicates with SEM presented.
Gene Expression and qPCR
Relative gene expression was performed through mRNA isolation from MDA231, MDA-468, and HEK293T cell lines using Invitrogen Cell to Ct kit (Life
Technologies #4399002). Following the manufacturers’ recommendations, the cells were
plated in a 96-well plate, and the untreated cells were grown to 75% confluency. For
transfection, 0.1 μg of plasmid DNA was added with Fugene 6 transfection reagent in a
1:6 ratio (plasmid DNA to Fugene). Cells were then allowed 48h to recover before being
lysed for mRNA isolation using an Invitrogen Cell to Ct kit (Life Technologies
#4399002). The cells were then lysed, and RT-PCR was performed to produce cDNA
using the reagents from the kit. After cDNA synthesis, qPCR was performed using
TaqMan Gene expression primers POLB (Thermo Fisher #Hs01099715_m1) and PARP1
(Thermo Fisher #Hs0024302_m1), and the TaqMan master mix provided with the kit
(Applied Biosystems Foster City, CA, USA #4369016). The assay was performed in
technical triplicate over three biological replicates. Results represent the average of the
three biological replicates ± standard error of the mean (SEM).
Modulation of STAT3
Plasmid constructs for stable depletion of human STAT3 mRNA, pSIH-puroSTAT3 shRNA (referred two as shRNA #1), and its control were gifts from Frank
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Sinicrope (Addgene plasmid #26596 and #26597; Watertown, MA, USA). An additional
shRNA construct specific for STAT3 (shRNA Clone ID:NM_003150.3-458s21c1
referred to as shRNA #2 hereafter) and the pLKO.1 control were purchased from SigmaAldrich (St. Louis, MO, USA). Both shRNA constructs and their controls were used to
validate the STAT3 binding site and expression changes. MDA-231 cells were plated at
200,000 cells/well in a 6-well culture plate. After 48h, cells were transfected with 5 μg
plasmid DNA (shRNA# 1 or 2 or appropriate vector control) and FuGene 6 (Promega) at
a 1:6 ratio (DNA to FuGene). Cells were allowed to recover for 48h following
transfection. STAT3 was overexpressed using a pcDNA3.1+ STAT3 ORF clone from
Genscript (Piscataway, NJ, USA) with a C-terminal Flag-tag. MDA-231 cells were plated
at 200,000 cells/well in a 6-well culture plate, and HEK293T were plated in 10cm plates
at 500,000 cells/plate. After 48 h, MDA-231 cells were transfected with 5μg of plasmid
DNA (STAT3-FLAG and proper vector control) and Fugene 6 (Promega) in a 1:6 ratio
(DNA to Fugene). HEK239T cells were transfected with 10 μg of plasmid DNA
(STAT3-FLAG and proper vector control) and Jetprime transfection agent at a 1:2 ratio
(DNA to Jetprime). 48 h post-transfection, cells were rinsed with 1X PBS, plates were
scraped, and the pelleted cells were stored overnight at −80°C. Immunoblot was then
performed as described below.
Cytokine Exposure
Cytokine exposure was performed using recombinant Human IL-6 protein (R&D
Systems, Minneapolis, MN, USA, #206-IL-010/CF). IL-6 was aliquoted in PBS at 100
µg/mL concentration and stored at −80°C for no longer than three months before use, as
recommended by the manufacturers. Aliquoted IL-6 was added to the cell culture
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medium to a final concentration of 50ng/mL. MDA-231 and HEK293T cells were plated
in 15 mm dishes and cultured to 70–80% confluency. Cells were then exposed to IL-6 at
a final concentration of 50ng/mL for 30 min, 1 h, and 4 h. Cells rinsed with 1X PBS
plates were scraped, and pelleted cells were stored overnight at −80°C. Immunoblot was
performed as described above.
Statistical Analysis
Assays were performed as three biological replications. One-way ANOVA and
means were compared with Dunnett’s post hoc analysis. Comparison groups are indicated
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in graphs. All means are reported ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001,
**** p < 0.0001.

Results
STAT3 shows significant enrichment at the POLB promoter

Figure 4.1. STAT3 shows significant enrichment at the POLB promoter in TNBC
cell lines; A) MDA-468 STAT3 ChIP of the POLB promoter mapping of STAT3
binding compared IgG controls B) MDA-231 STAT3 ChIP of the POLB promoter
compared IgG controls * p < 0.05 ** p < 0.01,*** p< 0.001, **** p < 0.0001.

A potential STAT3 binding site in the POLB promoter was first identified via an
IgV browser in silico search. IgV browser, as previously described, was used to identify a
potential consensus binding sequence for STAT3 in the POLB promoter. ChIP analysis of
the POLB promoter showed increased STAT3 enrichment in MDA-468 (2.2 ± 0.14) and
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MDA-231 (2.2 ± 0.46) enrichment at a 133 base pair region ( -549 to -416) within the
POLB promoter and increased STAT3 enrichment in MDA-468 (1.7 ± 0.11) (Figure
4.1A) and MDA-231 (1.8 ± 0.20) at an overlapping 113 base pair region (-507 to -394)
compared to the respective IgG controls (Figure 4.1B).
Modulation of STAT3 alters expression of POL 𝜷

Figure 4.2. Attenuation of STAT3 alters expression of POL 𝛽 in MDA-231 ; A)
Representative western blot for pSTAT3, STAT3, and POL 𝛽 with tubulin used as
the loading control B) Quantification of POL 𝛽 protein expression from 3 westerns
blots, values displayed as mean ± SEM compared to vector controls C)
Quantification of POLB gene expression analysis, values displayed as mean ± SEM
compared to vector controls * p < 0.05 ** p < 0.01,*** p< 0.001, **** p < 0.0001.

We next wanted to further confirm a role for STAT3 in regulating POL 𝛽
expression. STAT3 expression was attenuated using two different shRNA constructs, and
subsequent alterations in POL 𝛽 protein and gene expression were monitored. Following
shRNA-mediated knockdown of STAT3, POLB gene expression was attenuated in
MDA-231 (sh#1 0.468 ± 0.088 and sh #2 0.69 ± 0.038) (Figure 4.2C). The reduction of
POLB gene expression translated to a reduction in POL 𝛽 protein expression compared to
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respective vector controls (sh#1 0.42 ± 0.04 and sh #2 0.50 ± 0.04) (Figure 4.2A and B).
Reduced POLB gene expression for both shRNA constructs also occurred in MDA-468
(Figure 4.3C) (sh#1 0.67 ± 0.08 and sh #2 0.61 ± 0.02).

Figure 4.3. Attenuation of STAT3 alters expression of POL 𝛽 in MDA-468 ; A)
Representative western blot for pSTAT3, STAT3, and POL 𝛽 with tubulin used as the
loading control B) Quantification of POL 𝛽 protein expression from 3 westerns blots, values
displayed as mean ± SEM compared to vector controls C) Quantification of POLB gene
expression analysis, values displayed as mean ± SEM compared to vector controls * p <
0.05 ** p < 0.01,*** p< 0.001, **** p < 0.0001.

Reduced POLB gene expression resulted in attenuated POL 𝛽 protein expression
(sh#1 0.67 ± 0.03 and sh #2 0.44 ± 0.09) (Figure 4.3A and B). Ectopic expression of
STAT3 using STAT3-FLAG overexpression vector was used to test the effect of
increased STAT3 expression on POL 𝛽 expression. Following STAT3-FLAG
transfection, immunoblotting and gene expression analysis revealed an increase in POL 𝛽
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protein and POLB gene expression in MDA-231 (1.6 ± 0.09 and 1.8 ± 0.14,
respectively) (Figure 4.4A, B, and C).

Figure 4.4. Ectopic expression of STAT3 increases expression of POL 𝛽 ; A)
Representative western blot for pSTAT3, STAT3, and POL 𝛽 with 𝛼tubulin used as the
loading control B) Quantification of POL 𝛽 protein expression from 3 westerns blots,
values displayed as mean ± SEM compared to vector controls C) Quantification of POLB
gene expression analysis, values displayed as mean ± SEM compared to vector controls
* p < 0.05 ** p < 0.01,*** p< 0.001, **** p < 0.0001.

Pharmacological inhibition of STAT3 attenuates POL 𝜷 expression
To further confirm a regulatory role for STAT3 in POL 𝛽 expression, we next
wanted to test the effect that inhibition of STAT3 activation had on POL 𝛽 expression.
STAT3 activation was attenuated by exposing cells with 15𝜇M alantolactone for 4 h.
Subsequent immunoblotting revealed a reduction of POL 𝛽 protein expression in both
MDA-231 and MDA-468 (0.54 ± 0.19 and 0.72 ± 0.01, respectively) (Figure 4.5A, B,
D, and E). Gene expression analysis also revealed that reduced STAT3 activation resulted
in a significant reduction in POLB gene expression following alantolactone treatment in
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both MDA-231 and MDA-468 (0.77 ± 0.04 and 0.74 ± 0.05, respectively)(Figure 4.5C
and F).

Figure 4.5. Pharmacological inhibition of STAT3 attenuates POL 𝛽 expression; A)
MDA-231 representative western blot following 15𝜇M alantolactone for 4 h for pSTAT3,
STAT3, and POL 𝛽 with tubulin used as the loading control B) Quantification of POL 𝛽
protein expression in MDA-231 from 3 westerns blots following 15𝜇M alantolactone for
4 h, values displayed as mean ± SEM compared to vector controls C) Quantification of
POLB gene expression analysis of MDA-231 following 15𝜇M alantolactone for 4 h,
values displayed as mean ± SEM compared to vector controls D) MDA-468
representative western blot following 15𝜇M alantolactone for 4 h for pSTAT3, STAT3,
and POL 𝛽 with tubulin used as the loading control E) Quantification of POL 𝛽 protein
expression in MDA-468 from 3 westerns blots following 15𝜇M alantolactone for 4 h,
values displayed as mean ± SEM compared to vector controls F) Quantification of
POLB gene expression analysis of MDA-468, values displayed as mean ± SEM
compared following 15𝜇M alantolactone for 4 h to vector controls * p < 0.05 ** p <
0.01,*** p< 0.001, **** p < 0.0001.
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Binding of STAT3 to the POLB promoter in HEK293T requires STAT3 activation
Next, the binding of STAT3 to the POLB promoter in the non-tumorigenic cell
line HEK293T was assessed using ChIP. Similar to XRCC1, the enrichment of STAT3 at
the POLB promoter was low under basal conditions in HEK293T in the overlapping
POLB regions (1.3 ± 0.06 and 0.98 ± 0.50) (Figure 4.6) compared to the enrichment in
MDA-231 (2.2 ± 0.46 and 1.8 ± 0.20). We next wanted to see if the binding of STAT3
to the POLB promoter could be stimulated through increases in STAT3 expression or
increased STAT3 activation. Using the STAT3-FLAG ectopic expression vector, STAT3
expression was increased in HEK293T cells, and ChIP analysis revealed increased
STAT3 enrichment at the POLB promoter at the overlapping regions (3.5 ± 0.68 and 2.6
± 0.59) comparable to the enrichment in the TNBC cell line, MDA-231 (2.2 ± 0.46 and
1.8 ± 0.20) (Figure 4.6A). STAT3 activation in the HEK293T was stimulated through the
exposure of 50 ng/mL IL-6 for 4 h, which was previously shown to stimulate XRCC1
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protein and gene expression as well as STAT3 binding to the XRCC1 promoter in
HEK293T (Figure 2.).

Figure 4.6. Binding of STAT3 to the POLB promoter in non-TNBC cell line requires
STAT3 activation; A) HEK293T STAT3-FLAG STAT3 ChIP of the POLB promoter,
values normalized to respective IgG controls B) HEK293T STAT3 ChIP of the POLB
promoter following exposure of 50ng/mL IL-6 for 4 h, values normalized to respective
IgG controls * p < 0.05 ** p < 0.01,*** p< 0.001, **** p < 0.0001.

Following IL-6 exposure, STAT3 enrichment increased at the overlapping
binding regions in the POLB promoter (5.5 ± 1.3 and 4.6 ± 1.0) to a level similar to the
MDA-231 (2.2 ± 0.46 and 1.8 ± 0.20), which has constitutively active STAT3 (Figure
4.6B). Additionally, POLB gene expression increased at 30 min (1.6 ± 0.22) following
50ng/mL IL-6 exposure in HEK293T. A peak increase in POL 𝛽 protein expression
occurred at 1 h (2.4 ± 0.53) following 50 ng/mL IL-6 exposure in HEK293T (Figure
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4.7A, B). Similar increases in POL 𝛽 gene and protein expression were seen in MDA-231
with peaks in protein expression occurring at 30 min and 4 h (2.4 ± 0.12 and 2.7 ± 0.29)

Figure 4.7. IL-6 increases phospho-STAT3 and increases the expression of POL 𝛽 in
HEK293T and MDA-231. A) Representative immunoblot of phospho-STAT3 (Y705),
STAT3 and POL 𝛽 protein expression after 30 min, 1 h, and 4 h exposure to 50 ng/mL
IL-6 in HEK293T, α-tubulin is used as a loading control. B) Quantification of protein
expression changes in POL 𝛽 resulting from 50 ng/mL IL-6 in HEK293T. C)
Quantification of POLB mRNA expression following 50 ng/mL IL-6 in HEK293T. D)
Representative immunoblot of phospho-STAT3 (Y705), STAT3 and POL 𝛽 protein
expression after 30 min, 1 h, and 4 h exposure to 50 ng/mL IL-6 in MDA-231, α-tubulin
is used as a loading control. E) Quantification of protein expression changes in POL 𝛽
resulting from 50 ng/mL IL-6 in MDA-231. F) Quantification of POLB mRNA
expression following 50 ng/mL IL-6 in MDA-231. *p<0.05, **p< 0.01, ***p<0.001
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following IL-6 and peaks in gene expression at 1 h (1.69 ± 0.0438) (Figure 4.7D, E, and
F).
The PARP1 promoter does not contain a STAT3 binding site

Figure 4.8. The PARP1 promoter does not show significant STAT3 enrichment A)
MDA-231 STAT3 ChIP of the PARP1 promoter, normalized to respective IgG controls
B) MDA-468 STAT3 ChIP of the PARP1 promoter, normalized to respective IgG
controls C) HEK293T STAT3 ChIP of the PARP1 promoter, normalized to respective
IgG controls D) HEK293T STAT3 ChIP of the PARP1 promoter following exposure to
50ng/mL of IL-6 for 4 h, normalized to respective IgG controls * p < 0.05 ** p <
0.01,*** p< 0.001, **** p < 0.0001.
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We first assessed the potential for a STAT3 binding site within the PARP1
promoter using an in silico search with the IgV browser. A potential STAT3 binding site
was predicted within the PARP1 promoter. To further characterize the potential STAT3
binding site, STAT3 ChIP analysis was performed at the PARP1 promoter. No STAT3
enrichment was seen at the PARP1 promoter, indicating no strong STAT3 binding site
within the region for MDA-231 and MDA-468 (Figure 4.8A and B). No binding site was

Figure 4.9. Attenuation of STAT3 does not alter expression of PARP1 in MDA-231 ; A)
Representative western blot for pSTAT3, STAT3, and PARP1 with α-tubulin used as the
loading control B) Quantification of PARP1 protein expression from 3 westerns blots,
values displayed as mean ± SEM compared to vector controls C) Quantification of
PARP1 gene expression analysis, values displayed as mean ± SEM compared to vector
controls * p < 0.05 ** p < 0.01,*** p< 0.001, **** p < 0.0001.
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identified in the non-tumorigenic HEK293T (Figure 4.8C). Following stimulation with
IL-6, no STAT3 enrichment occurred at the PARP1 promoter (Figure 4.8D).
Differential expression of PARP1 following STAT3 modulation
Because of the many roles of PARP1, including modulation of STAT3 activity
through PARylation, we wanted to test how STAT3 modulation would alter protein and
gene expression of PARP1.
Using two shRNA constructs targeting different regions of STAT3, a STAT3
knockdown was performed. Subsequent gene expression analysis revealed no significant
changes in PARP1 gene expression following STAT3 knockdown in MDA-231 (sh#1
0.83 ± 0.12 and sh #2 1.3 ± 0.19) (Figure 4.9C) and MDA-468 (sh#1 0.89 ± 0.08 and sh
#2 0.88 ± 0.13) (Figure 4.10C). As expected STAT3 knockdown did not result in
reduced PARP1 in MDA-231 (sh#1 0.84 ± 0.01 and sh #2 1.1 ± 0.28) (Figure 4.9 A and
B) and MDA-468 (sh#1 0.93 ± 0.08 and sh #2 1.0 ± 0.15) (Figure 4.10A and B). To
further confirm that STAT3 does not have a strong regulatory role in the expression of
PARP1, we used the STAT3 inhibitor alantolactone. MDA-231 and MDA-468 cells were
dosed with 15𝜇M alantolactone for 4 h. Following alantolactone treatment, a non-
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significant change in PARP1 gene expression occurred in MDA-231 (0.88 ± 0.02) and in
MDA-468 (0.94 ± 0.05) compared to the respective DMSO control (Figure 4.11C and F).

Figure 4.10. Attenuation of STAT3 does not alter expression of PARP1 in MDA-468
; A) Representative western blot for pSTAT3, STAT3, and PARP1 with tubulin used
as the loading control B) Quantification of PARP1 protein expression from 3
westerns blots, values displayed as mean ± SEM compared to vector controls C)
Quantification of PARP1 gene expression analysis, values displayed as mean ± SEM
compared to vector controls * p < 0.05 ** p < 0.01,*** p< 0.001, **** p < 0.0001.

Immunoblots revealed a slight reduction of PARP1 protein expression in MDA468 (0.79 ± 0.07) and a non-significant reduction in MDA-231 (0.92 ± 0.25) (Figure
4.11 A, B, C, and D). These results were further confirmed by no changes in PARP1
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protein or gene expression following overexpression of STAT3 through the STAT3FLAG in MDA-231 (1.2 ± 0.10 and 1.2 ± 0.14, respectively) (Figure 4.12).

Figure 4.11. Pharmacological inhibition of STAT3 does not alter PARP1 expression A)
MDA-231 representative western blot following 15𝜇M alantolactone for 4 h for
pSTAT3, STAT3, and PARP1 with tubulin used as the loading control B) Quantification
of PARP1 protein expression in MDA-231 from 3 westerns blots following 15𝜇M
alantolactone for 4 h, values displayed as mean ± SEM compared to vector controls C)
Quantification of PARP1 gene expression analysis of MDA-231 following 15𝜇M
alantolactone for 4 h, values displayed as mean ± SEM compared to vector controls D)
MDA-468 representative western blot following 15𝜇M alantolactone for 4 h for
pSTAT3, STAT3, and PARP with tubulin used as the loading control E) Quantification
of PARP1protein expression in MDA-468 from 3 westerns blots following 15𝜇M
alantolactone for 4 h, values displayed as mean ± SEM compared to vector controls F)
Quantification of PARP1 gene expression analysis of MDA-468, values displayed as
mean ± SEM compared following 15𝜇M alantolactone for 4 h to vector controls * p <
0.05 ** p < 0.01,*** p< 0.001, **** p < 0.0001.
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Figure 4.12. Ectopic expression of STAT3 does not alter the expression of PARP1
A) Representative western blot for pSTAT3, STAT3, and PARP1 with tubulin used
as the loading control B) Quantification of POL 𝛽 protein expression from 3
westerns blots, values displayed as mean ± SEM compared to vector controls C)
Quantification of PARP1 gene expression analysis, values displayed as mean ±
SEM compared to vector controls * p < 0.05 ** p < 0.01,*** p< 0.001, **** p <
0.0001.

Discussion
Here we report that STAT3 is a novel regulator of POL 𝛽 in TNBC cell lines
MDA-231 and MDA-468. STAT3 regulation of POL 𝛽 occurs constitutively in MDA231 and MDA-468 through constitutive activation of STAT3. Attenuation of STAT3
through STAT3 knockdown and inhibition of STAT3 activation through alantolactone
treatment resulted in reduced POL 𝛽 expression at the protein and gene expression level.
In the non-tumorigenic cell line HEK293T, a low amount of STAT3 enrichment at the
POLB promoter was seen (1.3 ± 0.06 and 0.98 ± 0.50, for overlapping POLB promoter
regions) compared to the TNBC cell lines MDA-231 (2.2 ± 0.14 and 1.73 ± 0.11) and
MDA-468 (2.2 ± 0.46 and 1.8 ± 0.20). Given the regulatory mechanism identified for
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XRCC1, we wanted to test physiologically relevant exogenous exposures known to
stimulate STAT3. Interestingly, the binding of STAT3 to the POLB promoter was
stimulated by both the ectopic expression of STAT3 and STAT3 activation through IL-6
exposure. Expression of POL 𝛽 was also stimulated by exogenous exposure to IL-6 in
HEK293T similar to STAT3 occupancy of the XRCC1 promoter.
The regulation of BER proteins XRCC1 and POL 𝛽 by STAT3 suggested other
BER proteins may be altered by STAT3, including PARP1, which is also dysregulated in
TNBC cell lines. Although in silico searches revealed a potential STAT3 binding site
within the PARP1 promoter, ChIP revealed no STAT3 enrichment within the PARP1
promoter. Following shRNA-mediated knockdown of STAT3, no change in PARP1 gene
or protein expression occurred in TNBC cell lines MDA-231 and MDA-468.
Pharmacological inhibition of STAT3 using the STAT3 inhibitor alantolactone also
resulted in no PARP1 gene or protein expression changes. Finally, overexpression of
STAT3 using the STAT3-FLAG ectopic expression vector did not result in increased
PARP1 expression in MDA-231. Stimulation of STAT3 expression and activation
through ectopic expression and IL-6 exposure, respectively, did not stimulate binding in
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non-tumorigenic HEK293T. These data indicate STAT3 does not have a significant role
in the regulation PARP1 transcription.

Figure 4.13. Role of PARP1 in the regulation of STAT3 and STAT5 activity. PARP1
PARylates STAT3 and STAT5, reducing the activity of STAT3 and promoting the
activity of STAT5, which have been shown to have reciprocal functions. This Figure
was generated using Biorender.com with citation provided in Appendix B.

Interestingly, STAT3 is PARylated by PARP1, reducing the activity of STAT3,
while for STAT5, another STAT family member previously mentioned, PARylation
increases the activity of STAT5. An interesting explanation for the lack of STAT3
regulation of PARP1 arises when comparing the reciprocal functions of STAT3 and
STAT5 and the role PARP1 has in regulating their activity (Figure 4.13). STAT5 is
known to suppress the function of STAT3 and is activated following PARylation by
PARP1 46,48,123,124. STAT5 increases ROS production, increasing oxidative DNA damage
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and further stimulating PARP1 activation 123. On the other hand, STAT3 activity is
suppressed following PARylation 24. Thus, increased expression of PARP1 would
ultimately shut off regulation by STAT3 through both PARylation of STAT3 and
PARylation STAT5, which shuts off STAT3 regulation. Because STAT3 has been shown
to drive the regulation of XRCC1 and POL 𝛽, PARP1 regulation of STAT3 and STAT5
activity provide an additional mechanism for cells to prevent overexpression of BER
proteins. Yet these regulatory schemes are subverted in TNBC, contributing to its
aggressive nature.
Dysregulation of DNA repair proteins is a hallmark of cancer. Here we identified
that POL 𝛽 is regulated by STAT3, an oncogene constitutively activated in 70% of
human cancers, including TNBC 45,50. Because of the molecular status of TNBC,
molecularly targeted therapies are ineffective in the treatment of TNBC. Thus, DNA
damaging chemotherapeutics serve as first-line treatment options for patients with
TNBC. This work provides a novel link between STAT3 and POL 𝛽 and suggests that
constitutive activation may potentially serve as a novel biomarker for therapeutic
sensitivity and resistance through BER dysregulation. In addition to the role in
therapeutic response, POL 𝛽 overexpression has been documented to promote ‘mutator
phenotypes’ through genomic instability 29,98. This also provides a novel link to
inflammation and other conditions promoting STAT3 activation and increased genomic
instability through POL 𝛽, potentially promoting cancer formation and progression. Both
increased POL 𝛽 and increased STAT3 activation play a critical role in carcinogenesis
35,125.

Thus, sustained STAT3 activation, which commonly occurs in cancer, drives POL

𝛽 and XRCC1 expression. In concert, these could drive genomic instability and promote
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carcinogenesis. Future studies should work to futher delinate the role of STAT3 driven
overexpression of POL 𝛽 and XRCC1 on these processes.
This chapter describes work uncovering STAT3 as a novel constitutive regulator
of POL 𝛽 in TNBC cell lines MDA-231 and MDA-468 and a conditional regulator in the
non-tumorigenic HEK293T. This work could provide a novel biomarker that could be
used to determine the therapeutic response to some DNA damaging chemotherapeutics.
This work also provides a novel link between inflammation and POL 𝛽, potentially
promoting cancer through genomic instability. Although STAT3 was not shown to
regulate the expression of PARP1, PARP1 could serve as a barrier to BER protein
overexpression, promoting carcinogenic events through PARylation of STAT3 and
STAT5, effectively shutting of STAT3 regulation of BER proteins. The subversion of
this mechanism in TNBC requires further investigation and could provide new insight for
therapeutic intervention.
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CHAPTER V: CONCLUSIONS

Through this work, I have validated the hypothesis that STAT3 regulates the BER
proteins XRCC1, and POL 𝛽, though surprisingly does not regulate PARP1. Further, I
have uncovered this regulation scheme is highly relevant to TNBC, where constitutive
activation of STAT3 induced overexpression of these proteins and increased DNA repair.
For the first time, this work links the overexpression of BER proteins to STAT3 and
offers a potential explanation for the observed chemoresistance observed in TNBC.
Additionally, I have identified this STAT3-BER regulation axis occurs as a stress
response mechanism in other cell line models without constitutive activation of STAT3.
Using non-tumorigenic HEK293T, I have demonstrated exogenous stress and mitogenic
signal induce the overexpression of XRCC1 and POL 𝛽. This work highlights the
beneficial role the STAT3-BER regulation axis may play in normal cell growth and
development. More work is needed to understand the conditions under which this healthy
DNA damage response loop can be repurposed or reprogrammed in cancer development
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and progression. This work is a critical first step in understanding BER regulation in
cancer, which has been underappreciated to date.

Figure 5.1. STAT3 dysregulation of BER proteins: Exogenous exposures, including
EGF, IL-6, and Glucose, increase the activation of STAT3, subsequently increasing
the occupancy of STAT3 at the promoters of BER genes XRCC1 and POLB and
driving the expression of BER proteins, increasing DNA repair and promoting
chemoresistance and genomic instability. This Figure was generated using
Biorender.com with citation provided in Appendix B.

We also describe a novel link between high glucose exposure and increased
XRCC1 expression. Acute high glucose increased STAT3 occupancy of the XRCC1
promoter and subsequently increased XRCC1 expression. Increased XRCC1 expression
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following acute glucose exposure resulted in increased DNA repair and increased
resistance to the alkylating agent MMS. Low glucose adaptation (5mM) in HEK293T and
U2OS reduced the activation of STAT3 and expression of XRCC1. Adapting these cell
lines to high glucose (30mM) resulted in dysregulation of XRCC1 gene and protein
expression through sustained STAT3 activation. These data indicate a novel role for
inflammatory signaling and exogenous exposures, including dietary choices, on
regulating BER proteins and modulating DNA repair.

Figure 5.2. Dysregulation of XRCC1 promotes increased therapeutic resistance: At
homeostasis, acute exposures promote the rapid repair of DNA damage. Chronic
exogenous exposures promote sustained STAT3 activation, promoting dysregulation
of XRCC1 and therapeutic resistance. This Figure was generated using
Biorender.com with citation provided in Appendix B.

Differential XRCC1 expression changes in HEK293T, MDA-231, and U2OS
following exogenous exposures suggest changes in activating cytokines or mitogens and
their receptors that activate STAT3 are responsible for BER protein expression changes.
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We found that low release of IL-6, low EGFR activation and expression, and high IL6R𝛼 expression in HEK293T resulted in a highly inducible XRCC1 response upon
STAT3 activation. For U2OS, we identified moderate expression of EGFR, high basal
STAT3 activation, and high IL-6 release compared to MDA-231 and HEK293T, resulting
in an inducible but sustained high XRCC1 expression. Constitutive activation of STAT3
in MDA-231 is likely a result of the high activation and expression of EGFR and low IL6R𝛼 expression compared to HEK293T, resulting in high basal XRCC1 expression with
limited inducibility.
Chronic inflammation, hyperglycemia, and inflammatory signaling are common
in cancer. Here we identify that continuous exposure to glucose results in the
dysregulation of XRCC1 through sustained STAT3 activation in the non-tumorigenic cell
lines with limited modulation in the constitutively activated MDA-231. These data
indicated that upstream regulators of STAT3 activation play a critical role in the
modulation of DNA repair and the potential therapeutic responses following DNA
damaging agents (Figure 5.2).
DNA damaging chemotherapeutics have become a mainstay in the treatment of
most cancers. STAT3 plays a critical role in the formation and maintenance of many
cancers and is constitutively activated in 70% of human cancers. Additionally, BER
proteins XRCC1 and POL 𝛽 are overexpressed in a myriad of human cancers, including
breast, colorectal, and ovarian. Overexpression of BER proteins promotes genomic
instability, a hallmark of cancer, and resistance to DNA damaging chemotherapeutics,
including cisplatin. Here we identified a novel regulatory mechanism in which STAT3
promotes the dysregulation of BER proteins XRCC1 and POL 𝛽 (Figure 5.1). This
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regulation could serve as a novel avenue for cancer cells to gain resistance to DNA
damaging chemotherapeutics by increasing DNA repair. We have also shown that
sustained STAT3 activation promotes the dysregulation of XRCC1 in tumorigenic and
non-tumorigenic cell lines. These data indicate a role for sustained STAT3 activation in
promoting genomic instability and potentially promoting tumorigenesis.
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Appendix A: Authorship Rights
Chapter 1 figures and text from “Transcription dysregulation of base excision
repair proteins in breast cancer” published in DNA Repair were used with permission
from the publisher Elsevier per the author rights in Elsevier’s proprietary journals.
Chapter 2 figures and text from “Activated STAT3 Is a Novel Regulator of the
XRCC1 Promoter and Selectively Increases XRCC1 Protein Levels in Triple Negative
Breast Cancer” published in International Journal of Molecular Sciences was used in
accordance with the open access article distributed under the Creative Commons
Attribution License (CY BY 4.0)
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Appendix B: Biorender Figure Citation
Figures 1.1 was adapted from “Base Exicision Repair” (1996) using
Biorender.com, 1.5, 4.13, 5.1, and 5.2 were created with BioRender.com.
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Appendix C: ChIP Primers
Primer

Sequence

XRCC1 -564 to -457 Forward

TGGGCAACATGGCAAGA

XRCC1 -564 to -457 Reverse

CTCCTAAGTAGCTGGGATTACAC

XRCC1 -452 to -358 Forward

AGTGGGAGGATCCCTTGG

XRCC1 -452 to -358 Reverse

ACAGGGTCTTGCTCTCTCA

XRCC1 -312 to -236 Forward

AAAGATTTGCTTTCTCGGCTTC

XRCC1 -312 to -236 Reverse

CAGTCGCGCCTCTCTTC

XRCC1 -251 to -110 Forward

TTTCTTCCAGACACCAATCCC

XRCC1 -251 to -110 Reverse

TAGCAACGAGCGTTTCCTC

XRCC1 -127 to -16 Forward

AGGAAACGCTCGTTGCTAA

XRCC1 -127 to -16 Reverse

TCGGGCCTTTCAAACCC

XRCC1 SP1 Site Forward

ATTGGGAGGCGAGGCTA

XRCC1 SP1 Site Reverse

TCTCCAGAGCGGGAAGAG

POLB -704 to -582 Forward

CAGACTGTAAATTTCTCAGATGTAGG

POLB -704 to -582 Reverse

TTGCGGTAGGGACCAAATTA
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POLB -626 to -524 Forward

CTCCCTTTCTTGTGGTCTCTTC

POLB -626 to -524 Reverse

TGTTAGTACACCTGCCAACC

POLB -549 to -416 Forward

TGGTTGGCAGGTGTACTAAC

POLB -549 to -416 Reverse

TCTAAGGATACCGGGCAGT

POLB -507 to -394 Forward

CTGTTCTCGGCATGGTTCA

POLB -507 to -394 Reverse

TGGCGTCACACTGTCAAA

POLB -452 to -356 Forward

GCACTGGAGTGTGACTG

POLB -452 to -356 Reverse

CAATGCATGGCGCGTTT

PARP1 1 Forward

GTAACTGTGTCCGGGAAGG

PARP1 1 Reverse

CGCCAACTGCACCATGA

PARP1 2 Forward

GGCCATCATGGTGCAGTT

PARP1 2 Reverse

CGTACTCGACTCGATAGAGCTT

PARP1 3 Forward

ATGGCGGAGTCTTCGGATAA

PARP1 3 Reverse

CCGCCGTTCCCTGATAGATA

PARP1 4 Forward

GGGTCCTCCAAAGAGCTACTA
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PARP1 4 Reverse

ACCCAGGAAGTCTTACTTGATTTC

PARP1 5 Forward

GTTCCGTGGGCGTTCC

PARP1 5 Reverse

CCCTTTGATTGTTCTGTCCCT
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